[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 721
1. Settmacher U, Thelen A, Jonas S, Husmann I, Heise M, Neuhaus P: [Resection and reconstruction of the retrohepatic vena cava in combination with liver resections]. Zentralbl Chir; 2005 Apr;130(2):104-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Resection and reconstruction of the retrohepatic vena cava in combination with liver resections].
  • Liver resection combined with the resection and reconstruction of the vena cava represents the only potential curative therapy for malignant hepatic tumors with invasion of the vena cava.
  • We performed a liver resection with segmental replacement of the retrohepatic vena cava by synthetic grafts in 29 patients.
  • Four patients underwent a simultaneous exstirpation of the primary tumor (kidney or suprarenals).
  • Five patients revealed postoperative transient liver insufficiency, requiring temporary dialysis in three cases.
  • 18 patients died during the course of follow-up, 17 of these cases due to recurrent metastases of the primary disease.
  • Beside tumor exstirpation, extended liver resection and concomitant vena cava replacement may prevent embolism as well as the obstruction of the vena cava with lower extremity swelling and the possibility of developing a Budd Chiari syndrome.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Carcinoma, Hepatocellular / surgery. Hepatic Duct, Common. Klatskin Tumor / surgery. Liver / surgery. Liver Neoplasms / surgery. Vascular Neoplasms / surgery. Vena Cava, Inferior / surgery
  • [MeSH-minor] Adult. Aged. Blood Vessel Prosthesis. Chemoembolization, Therapeutic. Female. Follow-Up Studies. Humans. Intraoperative Complications. Male. Middle Aged. Neoadjuvant Therapy. Neoplasm Invasiveness. Polytetrafluoroethylene. Postoperative Complications. Survival Analysis. Time Factors

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. TEFLON .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15849651.001).
  • [ISSN] 0044-409X
  • [Journal-full-title] Zentralblatt für Chirurgie
  • [ISO-abbreviation] Zentralbl Chir
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


2. Heffernan ME, Garland SM, Kane MA: Global reduction of cervical cancer with human papillomavirus vaccines: insights from the hepatitis B virus vaccine experience. Sex Health; 2010 Sep;7(3):383-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Worldwide, prophylactic vaccines against two major human cancers are now commercially available: hepatitis B virus (HBV) vaccines (first licensed in 1982) against primary hepatocellular carcinoma and human papillomavirus (HPV) vaccines (first licensed 2006) against cervical cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / prevention & control. Global Health. Hepatitis B / epidemiology. Hepatitis B / prevention & control. Hepatitis B Vaccines / administration & dosage. Liver Neoplasms / epidemiology. Liver Neoplasms / prevention & control. Mass Vaccination. Papillomavirus Infections / epidemiology. Papillomavirus Infections / prevention & control. Papillomavirus Vaccines / administration & dosage. Sexually Transmitted Diseases, Viral / epidemiology. Sexually Transmitted Diseases, Viral / prevention & control. Uterine Cervical Neoplasms / epidemiology. Uterine Cervical Neoplasms / prevention & control
  • [MeSH-minor] Adolescent. Adult. Child. Cooperative Behavior. Cross-Cultural Comparison. Cross-Sectional Studies. Female. Health Education / statistics & numerical data. Health Plan Implementation / statistics & numerical data. Health Services Accessibility / statistics & numerical data. Health Surveys. Humans. Incidence. Interdisciplinary Communication. Male. Patient Acceptance of Health Care / statistics & numerical data. Program Evaluation. School Health Services / statistics & numerical data. Young Adult


3. Parikh PM, Fuloria J, Babu G, Doval DC, Awasthy BS, Pai VR, Prabhakaran PS, Benson AB: A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma. Trop Gastroenterol; 2005 Jul-Sep;26(3):115-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of gemcitabine and cisplatin in patients with advanced hepatocellular carcinoma.
  • The primary objective of this study was to determine the response rates of a combination of gemcitabine and cisplatin in unresectable hepatocellular carcinoma (HCC) in Indian patients.
  • [MeSH-major] Antineoplastic Agents / administration & dosage. Carcinoma, Hepatocellular / drug therapy. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Drug Therapy, Combination. Female. Humans. Male. Middle Aged. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16512457.001).
  • [ISSN] 0250-636X
  • [Journal-full-title] Tropical gastroenterology : official journal of the Digestive Diseases Foundation
  • [ISO-abbreviation] Trop Gastroenterol
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


Advertisement
4. Sasaki A, Nitta H, Otsuka K, Takahara T, Nishizuka S, Wakabayashi G: Ten-year experience of totally laparoscopic liver resection in a single institution. Br J Surg; 2009 Mar;96(3):274-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ten-year experience of totally laparoscopic liver resection in a single institution.
  • BACKGROUND: Recent developments in liver surgery include the introduction of laparoscopic liver resection.
  • The aim of the present study was to review a single institution's 10-year experience of totally laparoscopic liver resection (TLLR).
  • METHODS: Between May 1997 and April 2008, 82 patients underwent TLLR for hepatocellular carcinoma (HCC) (37 patients), liver metastases (39) and benign liver lesions (six).
  • Nine patients underwent simultaneous laparoscopic resection of colorectal primary cancer and synchronous liver metastases.
  • CONCLUSION: TLLR can be performed safely for a variety of primary and secondary liver tumours, and seems to offer at least short-term benefits in selected patients.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Laparoscopy. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Complications / etiology. Length of Stay. Liver Diseases / surgery. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications / etiology. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19224518.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Jeong SC, Aikata H, Katamura Y, Azakami T, Kawaoka T, Saneto H, Uka K, Mori N, Takaki S, Kodama H, Waki K, Imamura M, Shirakawa H, Kawakami Y, Takahashi S, Chayama K: Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma. World J Gastroenterol; 2007 Oct 28;13(40):5343-50
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of a 24-week course of interferon-alpha therapy after curative treatment of hepatitis C virus-associated hepatocellular carcinoma.
  • AIM: To assess whether a 24-wk course of interferon (IFN) could prevent hepatocellular carcinoma (HCC) recurrence and worsening of liver function in patients with hepatitis C virus (HCV)-infected patients after receiving curative treatment for primary HCC.
  • METHODS: Outcomes in 42 patients with HCV infection treated with IFN-alpha, after curative treatment for primary HCC (IFN group), were compared with 42 matched curatively treated historical controls not given IFN (non-IFN group).
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antiviral Agents / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Hepacivirus. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Case-Control Studies. Dose-Response Relationship, Drug. Female. Humans. Liver / physiology. Male. Middle Aged. Multivariate Analysis. Retrospective Studies. Secondary Prevention. Survival Rate

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17879404.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Antiviral Agents; 0 / Interferon-alpha
  • [Other-IDs] NLM/ PMC4171324
  •  go-up   go-down


6. Yu L, Sloane DA, Guo C, Howell CD: Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000. Clin Gastroenterol Hepatol; 2006 Mar;4(3):355-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for primary hepatocellular carcinoma in black and white Americans in 2000.
  • BACKGROUND & AIMS: The incidence of primary hepatocellular carcinoma (HCC) is greater in black Americans compared with white Americans.
  • There was no racial difference in the frequency of alcoholic and cryptogenic liver diseases and diabetes.
  • [MeSH-major] African Americans. Carcinoma, Hepatocellular / ethnology. Carcinoma, Hepatocellular / etiology. European Continental Ancestry Group. Liver Neoplasms / ethnology. Liver Neoplasms / etiology
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Child. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. United States / epidemiology


7. Leelawat K, Suksumek N, Leelawat S, Lek-Uthai U: Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients. Southeast Asian J Trop Med Public Health; 2007 Sep;38(5):881-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of VacA gene specific for Helicobactor pylori in hepatocellular carcinoma and cholangiocarcinoma specimens of Thai patients.
  • In order to investigate and compare the presence of Helicobacter pylori VacA in primary liver cancer specimens (12 hepatocellular carcinoma and 6 cholangiocarcinoma) and control liver specimens (7 non-primary liver cancer) from Thai patients who underwent liver resection, H. pylori VacA gene was assayed in extracted DNA by real-time polymerase chain reaction.
  • The selected amplicons revealed high homology compared with H. pylori VacA sequence. H. pylori VacA gene was detected in all primary liver cancer specimens and in 71% (5/7) of control liver specimens.
  • [MeSH-major] Bacterial Proteins / genetics. Carcinoma, Hepatocellular / microbiology. Cholangiocarcinoma / microbiology. Helicobacter Infections / microbiology. Helicobacter pylori / genetics. Liver Neoplasms / microbiology
  • [MeSH-minor] Adult. Aged. Base Sequence. Female. Humans. Male. Middle Aged. Molecular Sequence Data. Polymerase Chain Reaction / methods. Thailand

  • MedlinePlus Health Information. consumer health - Helicobacter Pylori Infections.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18041306.001).
  • [ISSN] 0125-1562
  • [Journal-full-title] The Southeast Asian journal of tropical medicine and public health
  • [ISO-abbreviation] Southeast Asian J. Trop. Med. Public Health
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Bacterial Proteins; 0 / VacA protein, Helicobacter pylori
  •  go-up   go-down


8. Yong TL, Bohmer R, Pande GK, Birks SE, Loh DC, Hewitt PM: Liver resection: a regional hospital experience. ANZ J Surg; 2010 Oct;80(10):710-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection: a regional hospital experience.
  • BACKGROUND: Liver resection is a significant operation usually limited to large metropolitan hospitals.
  • Liver resections were first performed at the Launceston General Hospital (LGH), a regional centre (bed capacity 280), in May 2000.
  • This is a summary of liver resection at LGH.
  • METHODS: Data of liver resections performed between May 2000 and March 2008 at LGH were collected retro-prospectively and reviewed with attention to patient survival, post-operative complications and mortality.
  • RESULTS: There were 102 consecutive liver resections during the study period.
  • There were 13 resections for primary liver malignancy, 2 from invasion by gallbladder carcinoma, 1 for contiguous invasion by gastric cancer and 19 were for benign conditions.
  • Patients with hepatocellular carcinoma had 3-year survival rate of 15% (median survival = 24 months).
  • CONCLUSION: Resection provides the best hope of cure for patients with primary or secondary hepatic malignancy.
  • With adequate expertise, liver resections can be performed safely in a regional hospital.
  • [MeSH-major] Hepatectomy / statistics & numerical data. Liver Neoplasms / surgery
  • [MeSH-minor] Adenocarcinoma / pathology. Adolescent. Adult. Aged. Aged, 80 and over. Colorectal Neoplasms / pathology. Female. Hospitals, General. Humans. Male. Middle Aged. Postoperative Complications. Prospective Studies. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] © 2010 The Authors. ANZ Journal of Surgery © 2010 Royal Australasian College of Surgeons.
  • [ErratumIn] ANZ J Surg. 2011 Jan;81(1-2):107
  • (PMID = 21040331.001).
  • [ISSN] 1445-2197
  • [Journal-full-title] ANZ journal of surgery
  • [ISO-abbreviation] ANZ J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


9. Li Q, Wang J, Juzi JT, Sun Y, Zheng H, Cui Y, Li H, Hao X: Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma. J Gastrointest Surg; 2008 Sep;12(9):1540-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clonality analysis for multicentric origin and intrahepatic metastasis in recurrent and primary hepatocellular carcinoma.
  • AIMS: To clarify the incidence of multicentric occurrence (MO) and intrahepatic metastasis (IM) for hepatocellular carcinoma (HCC) related to hepatitis B virus in China and to identify the differences between them.
  • METHODS: Histopathologic and genetic features of primary and recurrent tumors in 160 cases with HCC were analyzed.
  • By comparing the genetic information of loss of heterozygosity and microsatellite instability for 10 different markers between primary and recurrent tumor, 30.0% and 63.8% patients with recurrent HCC were considered to be MO and IM, respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Hepatitis B / epidemiology. Liver Neoplasms / genetics. Liver Neoplasms / pathology. Neoplasm Recurrence, Local / genetics. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Age Distribution. Biopsy, Needle. China / epidemiology. Cohort Studies. Female. Humans. Immunohistochemistry. Incidence. Kaplan-Meier Estimate. Loss of Heterozygosity. Male. Microsatellite Repeats. Middle Aged. Multivariate Analysis. Neoplasm Staging. Polymerase Chain Reaction. Probability. Regression Analysis. Retrospective Studies. Risk Assessment. Sex Distribution. Survival Analysis

  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Hepatol. 2003 Aug;39(2):215-21 [12873818.001]
  • [Cites] Eur J Cancer Prev. 2003 Aug;12(4):273-9 [12883379.001]
  • [Cites] Gastroenterology. 2004 Sep;127(3):756-63 [15362032.001]
  • [Cites] Eur J Surg Oncol. 2005 Oct;31(8):845-53 [15979269.001]
  • [Cites] Clin Cancer Res. 2002 Jul;8(7):2266-72 [12114430.001]
  • [Cites] J Gastroenterol Hepatol. 2002 Apr;17(4):394-400 [11982718.001]
  • [Cites] J Gastroenterol Hepatol. 2005 Apr;20(4):536-46 [15836701.001]
  • [Cites] World J Surg. 1997 Oct;21(8):860-4; discussion 864-5 [9327679.001]
  • [Cites] Hepatol Res. 2004 May;29(1):24-30 [15135343.001]
  • [Cites] World J Surg. 2006 Mar;30(3):439-45 [16479331.001]
  • [Cites] J Pathol. 2003 Mar;199(3):345-53 [12579536.001]
  • [Cites] J Gastroenterol Hepatol. 2003 Apr;18(4):430-6 [12653892.001]
  • [Cites] Hepatology. 1994 Apr;19(4):889-94 [8138262.001]
  • [Cites] Gastric Cancer. 2006;9(2):51-66 [16767357.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 2001;8(4):353-9 [11521181.001]
  • [Cites] J Gastroenterol Hepatol. 1994 Nov-Dec;9(6):624-30 [7532451.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2005 May;17(5):497-503 [15827439.001]
  • [Cites] Int J Oncol. 2000 Sep;17(3):507-12 [10938391.001]
  • [Cites] J Hepatobiliary Pancreat Surg. 1998;5(1):86-92 [9683759.001]
  • [Cites] Hepatology. 1999 May;29(5):1446-52 [10216128.001]
  • [Cites] Jpn J Cancer Res. 1994 Oct;85(10):1040-4 [7961106.001]
  • [Cites] Cancer. 2000 Aug 1;89(3):500-7 [10931448.001]
  • [Cites] J Gastroenterol Hepatol. 2005 May;20(5):752-8 [15853990.001]
  • [Cites] Hepatology. 1997 Jan;25(1):87-92 [8985270.001]
  • [Cites] Gastroenterology. 2000 Aug;119(2):431-40 [10930378.001]
  • [Cites] J Viral Hepat. 2005 May;12(3):325-9 [15850475.001]
  • (PMID = 18629593.001).
  • [ISSN] 1873-4626
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


10. Higgs MR, Lerat H, Pawlotsky JM: Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest. Cancer Res; 2010 Jun 15;70(12):4901-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Downregulation of Gadd45beta expression by hepatitis C virus leads to defective cell cycle arrest.
  • Members of the Gadd45 family play central roles in the cellular response to genotoxic stress and have been implicated in several human cancers, including hepatocellular carcinomas.
  • Chronic infection by hepatitis C virus (HCV) is a major risk factor for the onset and development of primary hepatocellular tumors, although the underlying mechanisms are unclear.
  • Inhibited Gadd45beta expression was observed in both nontumoral and tumoral tissues from infected individuals, and in cell lines harboring a HCV replicon and the infectious HCV strain JFH1.
  • Diminished Gadd45beta expression leads to aberrant cell cycle arrest and diminished DNA excision repair.
  • Together, these results provide a novel insight into the mechanisms involved in HCV-associated hepatocellular carcinomas, showing that reduced Gadd45beta expression may play a contributory role to this process, and providing evidence that HCV may interfere with epigenetic gene expression by altering promoter methylation.
  • [MeSH-major] Antigens, Differentiation / metabolism. Carcinoma, Hepatocellular / metabolism. Hepatitis C / metabolism. Liver Neoplasms / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Blotting, Western. Cell Cycle. Cells, Cultured. DNA Methylation. DNA Repair. Down-Regulation. Female. Hepacivirus / physiology. Hepatocytes / cytology. Hepatocytes / metabolism. Humans. Liver / metabolism. Liver / virology. Luciferases / metabolism. Male. Mice. Mice, Inbred C57BL. Mice, Transgenic. Middle Aged. Promoter Regions, Genetic / genetics. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / pharmacology. Reverse Transcriptase Polymerase Chain Reaction. Virus Replication

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Hepatitis C.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • HAL archives ouvertes. Full text from .
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 1996 Jun 20;12(12):2579-94 [8700517.001]
  • [Cites] Ann Intern Med. 1992 Jan 15;116(2):97-102 [1309286.001]
  • [Cites] Nat Med. 1998 Sep;4(9):1065-7 [9734402.001]
  • [Cites] Cell. 1998 Nov 13;95(4):521-30 [9827804.001]
  • [Cites] Int J Cancer. 1999 Mar 15;80(6):875-9 [10074921.001]
  • [Cites] J Biol Chem. 2005 Nov 18;280(46):38544-55 [16144844.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):10830-7 [16322229.001]
  • [Cites] J Virol. 2006 Jul;80(14):7199-207 [16809325.001]
  • [Cites] Gut. 2006 Dec;55(12):1801-8 [16581947.001]
  • [Cites] Nat Protoc. 2006;1(5):2353-64 [17406479.001]
  • [Cites] Am J Pathol. 2007 Jul;171(1):287-96 [17591973.001]
  • [Cites] Blood Cells Mol Dis. 2007 Nov-Dec;39(3):329-35 [17659913.001]
  • [Cites] J Viral Hepat. 2007 Dec;14(12):821-9 [18070284.001]
  • [Cites] Gastroenterology. 2008 Jan;134(1):226-38 [18166355.001]
  • [Cites] J Mol Biol. 2008 Apr 18;378(1):97-111 [18343408.001]
  • [Cites] J Virol. 2008 Oct;82(19):9639-46 [18667510.001]
  • [Cites] Cell. 2008 Dec 26;135(7):1201-12 [19109892.001]
  • [Cites] PLoS Pathog. 2009 Jan;5(1):e1000269 [19148281.001]
  • [Cites] Cell Cycle. 2009 May 15;8(10):1526-31 [19377292.001]
  • [Cites] Hepatology. 2009 Nov;50(5):1370-9 [19711428.001]
  • [Cites] J Biol Chem. 2009 Nov 27;284(48):33466-74 [19808675.001]
  • [Cites] Eur J Immunol. 2009 Nov;39(11):3010-8 [19688743.001]
  • [Cites] Gastroenterology. 2010 Mar;138(3):1112-22 [19962982.001]
  • [Cites] J Viral Hepat. 2003 Jul;10(4):249-55 [12823590.001]
  • [Cites] Mol Cell Biol. 2000 May;20(10):3705-14 [10779360.001]
  • [Cites] J Biol Chem. 2000 Jun 2;275(22):16810-9 [10828065.001]
  • [Cites] Nat Rev Genet. 2000 Oct;1(1):11-9 [11262868.001]
  • [Cites] Microbiol Immunol. 2001;45(10):689-97 [11762751.001]
  • [Cites] Genes Dev. 2002 Jan 1;16(1):6-21 [11782440.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 8;99(1):184-9 [11756692.001]
  • [Cites] Gastroenterology. 2002 Feb;122(2):352-65 [11832450.001]
  • [Cites] Virology. 2002 Mar 1;294(1):94-105 [11886269.001]
  • [Cites] Oncogene. 2002 Jul 18;21(31):4801-11 [12101418.001]
  • [Cites] J Cell Physiol. 2002 Sep;192(3):327-38 [12124778.001]
  • [Cites] Hepatology. 2002 Aug;36(2):427-32 [12143052.001]
  • [Cites] J Biol Chem. 2003 Oct 31;278(44):43001-7 [12933797.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S74-83 [12407579.001]
  • [Cites] Am J Pathol. 2003 Jun;162(6):1961-74 [12759252.001]
  • [Cites] Mol Biol Rep. 2003 Dec;30(4):249-53 [14672412.001]
  • [Cites] Gastroenterology. 2004 Mar;126(3):859-72 [14988840.001]
  • [Cites] Oncogene. 2004 Apr 1;23(14):2472-83 [14968111.001]
  • [Cites] J Biol Chem. 2004 Sep 10;279(37):39075-84 [15262964.001]
  • [Cites] Am J Pathol. 2004 Nov;165(5):1689-99 [15509538.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Sep;87(17):6547-9 [2168552.001]
  • [Cites] J Virol. 1998 Jan;72(1):266-72 [9420223.001]
  • (PMID = 20530689.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Differentiation; 0 / GADD45B protein, human; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ HALMS495496; NLM/ PMC3125696
  •  go-up   go-down


11. Perry JF, Charlton B, Koorey DJ, Waugh RC, Gallagher PJ, Crawford MD, Verran DJ, McCaughan GW, Strasser SI: Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation. Liver Int; 2007 Nov;27(9):1240-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of patients with hepatocellular carcinoma referred to a tertiary centre with availability of multiple treatment options including cadaveric liver transplantation.
  • Hepatocellular carcinoma (HCC) is a primary cancer of the liver with an established causal link to viral hepatitis and other forms of chronic liver disease.
  • Surgical resection was primary treatment in 43 patients, liver transplantation in 40 patients, local ablation (percutaneous radiofrequency ablation or alcohol injection) in 33 patients, transarterial chemoembolisation in 33 patients, chemotherapy or other systemic therapy in 30 patients and no treatment in 56 patients.
  • After adjustment for significant covariates, both liver transplantation (P<0.001) and surgical resection (P=0.029) had a significant effect on patient survival compared with no treatment, but local ablation (P=0.410) and chemoembolisation (P=0.831) did not.
  • Liver transplantation resulted in superior overall and, in particular, disease-free survival compared with surgical resection (disease-free survival 84 vs 15% at 5 years).
  • CONCLUSION: In conclusion, both surgical resection and liver transplantation significantly improve the survival of patients with HCC, but improvements need to be made to the delivery of loco-regional therapy to enhance its effectiveness.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation. Chemoembolization, Therapeutic. Hepatectomy. Liver Neoplasms / therapy. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease-Free Survival. Female. Humans. Male. Middle Aged. Prospective Studies. Referral and Consultation. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17919236.001).
  • [ISSN] 1478-3223
  • [Journal-full-title] Liver international : official journal of the International Association for the Study of the Liver
  • [ISO-abbreviation] Liver Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


12. Chen LW, Lin J, Chen W, Zhang W: [Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Sep;25(9):832-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of Chinese herbal medicine on patients with primary hepatic carcinoma in III stage during perioperational period: a report of 42 cases].
  • CONCLUSION: Administration of compound Chinese herbal medicine in peri-operational period has definite effect on primary hepatic carcinoma in III stage, it can improve patients' immune function, decrease the recurrence rate and increase the cumulative survival rate.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16250104.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal
  •  go-up   go-down


13. Treska V, Skalický T, Sutnar A, Liska V, Ferda J, Mírka H, Slauf F, Duras P, Kreuzberg B: [Portal vein branch embolization in patients with primary inoperable liver tumors]. Rozhl Chir; 2010 Sep;89(9):456-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Portal vein branch embolization in patients with primary inoperable liver tumors].
  • INTRODUCTION: Portal vein embolization (PVE) is indicated in patients with insufficient liver remnants following liver resections for tumor disorders.
  • Therefore, due to PVE, the number of primary operable patients is higher.
  • Insufficient growth of the liver parenchyma or malignant progression remain the PVE cons.
  • METHODS: 40 patients (35 with colorectal carcinoma metastases, 2 with breast carcinoma metastases and one with ovarian carcinoma metastases, 2 with hepatocellular carcinoma) were indicated for PVE due to insufficient liver reserve following planned liver resection.
  • RESULTS: Liver resections were completed in 22 subjects, 42.6 days (mean value) after PVE.
  • In 14 (35%) subjects, the liver resection could not be performed (11x tumor progression, 3x insufficient liver tissue growth).
  • CONCLUSION: PVE has become an established procedure in stage liver procedures, due to its potential to facilitate operability of primary and secondary liver tumors.
  • In order to improve the outcomes, attention must be paid to the post- PVE growth of the liver parenchyma and further assessment of oncological treatment approaches during the pre- and post- PVE period, with the aim to reduce liver and extra-liver malignant progression rates prior to the liver resection procedure.
  • [MeSH-major] Embolization, Therapeutic. Liver Neoplasms / therapy. Portal Vein
  • [MeSH-minor] Adult. Aged. Cone-Beam Computed Tomography. Female. Hepatectomy. Humans. Liver / pathology. Liver / radiography. Liver Function Tests. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21121156.001).
  • [ISSN] 0035-9351
  • [Journal-full-title] Rozhledy v chirurgii : měsíčník Československé chirurgické společnosti
  • [ISO-abbreviation] Rozhl Chir
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Czech Republic
  •  go-up   go-down


14. Kim J, Hong SJ, Lim EK, Yu YS, Kim SW, Roh JH, Do IG, Joh JW, Kim DS: Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis. J Exp Clin Cancer Res; 2009;28:20
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of nicotinamide N-methyltransferase in hepatocellular carcinoma is associated with poor prognosis.
  • BACKGROUND: Hepatocellular carcinoma (HCC) is the most common tumor in the adult liver, with high relapse and mortality rates despite diverse treatment modalities.
  • METHODS: Frozen tumors and non-cancerous surrounding tissues from 120 patients with primary HCC were studied.
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. Liver Neoplasms / enzymology. Nicotinamide N-Methyltransferase / biosynthesis
  • [MeSH-minor] Adult. Aged. Biomarkers, Tumor / biosynthesis. Biomarkers, Tumor / genetics. Biomarkers, Tumor / metabolism. Cohort Studies. Disease-Free Survival. Female. Gene Expression. Humans. Male. Middle Aged. RNA, Messenger / biosynthesis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Jpn J Cancer Res. 1991 Nov;82(11):1277-83 [1836457.001]
  • [Cites] Clin Chim Acta. 1990 Jan 31;186(3):359-74 [2311261.001]
  • [Cites] J Biol Chem. 1994 May 20;269(20):14835-40 [8182091.001]
  • [Cites] J Hepatol. 1994 Jan;20(1):138-42 [8201215.001]
  • [Cites] Cancer. 1954 May;7(3):462-503 [13160935.001]
  • [Cites] Oncol Res. 2004;14(10):491-9 [15559763.001]
  • [Cites] Mol Endocrinol. 2005 Feb;19(2):527-39 [15486044.001]
  • [Cites] J Pathol. 2005 Feb;205(3):377-87 [15682440.001]
  • [Cites] Toxicol Pathol. 2005;33(1):175-80 [15805069.001]
  • [Cites] Semin Liver Dis. 2005;25(2):212-25 [15918149.001]
  • [Cites] Clin Cancer Res. 2005 Sep 15;11(18):6550-7 [16166432.001]
  • [Cites] J Urol. 2006 Nov;176(5):2248-54 [17070307.001]
  • [Cites] Exp Mol Med. 2006 Oct 31;38(5):455-65 [17079861.001]
  • [Cites] BMC Bioinformatics. 2007;8:66 [17326819.001]
  • [Cites] J Cancer Res Clin Oncol. 2008 May;134(5):551-9 [17922140.001]
  • [Cites] Clin Cancer Res. 2008 Aug 1;14(15):4814-20 [18676753.001]
  • [Cites] N Engl J Med. 2008 Nov 6;359(19):1995-2004 [18923165.001]
  • [Cites] Oncogene. 2008 Nov 6;27(52):6679-89 [18724390.001]
  • [Cites] Cancer Res. 2008 Nov 15;68(22):9167-75 [19010888.001]
  • [Cites] Physiol Genomics. 2001 Feb 7;5(1):21-33 [11161003.001]
  • [Cites] Cancer Res. 2001 Mar 1;61(5):2129-37 [11280777.001]
  • [Cites] Oncogene. 2001 Jul 27;20(33):4568-75 [11494152.001]
  • [Cites] J Neuropathol Exp Neurol. 2002 Feb;61(2):111-24 [11853016.001]
  • [Cites] Hepatology. 2002 May;35(5):1237-46 [11981774.001]
  • [Cites] Cancer Res. 2002 Jul 15;62(14):3939-44 [12124323.001]
  • [Cites] Nat Genet. 2002 Aug;31(4):339-46 [12149612.001]
  • [Cites] Genome Biol. 2002 Jun 18;3(7):RESEARCH0034 [12184808.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S136-49 [12591191.001]
  • [Cites] Neurosci Lett. 2003 May 15;342(1-2):13-6 [12727306.001]
  • [Cites] Curr Mol Med. 2003 Sep;3(6):573-88 [14527088.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Oct;88(10):4990-6 [14557485.001]
  • [Cites] Cancer Cell. 2004 Aug;6(2):129-37 [15324696.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S51-5 [15508103.001]
  • [Cites] Gastroenterology. 1981 Oct;81(4):668-75 [7262512.001]
  • [Cites] Hepatology. 1988 Jan-Feb;8(1):65-8 [3338721.001]
  • [Cites] Arch Biochem Biophys. 1988 Feb 1;260(2):601-8 [2963591.001]
  • [Cites] Tumour Biol. 1994;15(1):7-16 [8146531.001]
  • (PMID = 19216803.001).
  • [ISSN] 1756-9966
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; EC 2.1.1.1 / NNMT protein, human; EC 2.1.1.1 / Nicotinamide N-Methyltransferase
  • [Other-IDs] NLM/ PMC2657806
  •  go-up   go-down


15. Demir M, Serin E, Göktürk S, Ozturk NA, Kulaksizoglu S, Ylmaz U: The prevalence of occult hepatitis B virus infection in type 2 diabetes mellitus patients. Eur J Gastroenterol Hepatol; 2008 Jul;20(7):668-73
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CONCLUSION: These data suggest that the prevalence of occult HBV infection is higher in diabetics compared with healthy controls and this may contribute to the increased prevalence of primary hepatocellular carcinoma in diabetics.
  • [MeSH-minor] Adult. Alanine Transaminase / blood. Blood Donors. Carrier State / virology. Case-Control Studies. DNA, Viral / blood. Female. Hepatitis B Antibodies / blood. Hepatitis B Core Antigens / immunology. Hepatitis B Surface Antigens / immunology. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged


16. Hwangbo Y, Jung JH, Shim J, Kim BH, Jung SH, Lee CK, Jang JY, Dong SH, Kim HJ, Chang YW, Chang R: [Etiologic and laboratory analyses of ascites in patients who underwent diagnostic paracentesis]. Korean J Hepatol; 2007 Jun;13(2):185-95
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Liver cirrhosis and malignant tumors are two major causes of ascites according to the reports from Western countries, 80% and 10% respectively.
  • Among cancer-related ascites, peritoneal carcinomatosis type was 75.5% (primary sites: stomach 24.5%, pancreas 15.9%, colon 15.9%, lung 7.4%, etc), metastatic liver cancers 8.5%, hepatocellular carcinoma without cirrhosis 6.4%, etc.
  • CONCLUSIONS: Liver cirrhosis is the leading cause of ascites, especially alcoholic cirrhosis has significantly increased.
  • [MeSH-major] Liver Cirrhosis / diagnosis. Liver Cirrhosis, Alcoholic / diagnosis. Neoplasms / diagnosis. Paracentesis. Peritonitis, Tuberculous / diagnosis
  • [MeSH-minor] Adenosine Deaminase / analysis. Adult. Aged. Ascitic Fluid / chemistry. Ascitic Fluid / pathology. Female. Humans. Male. Middle Aged. Predictive Value of Tests. Prevalence. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585192.001).
  • [ISSN] 1738-222X
  • [Journal-full-title] The Korean journal of hepatology
  • [ISO-abbreviation] Korean J Hepatol
  • [Language] kor
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] EC 3.5.4.4 / Adenosine Deaminase
  •  go-up   go-down


17. Chen Y, Lin YY, Hu MH, Chen YS: [Clinical research of AFP variant with microcentrifugalcolumn method and crossed affinity immunoelectrophoresis autoradiography method]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2008 Oct;22(5):379-81
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: To compare the clinical value of microcentrifugalcolumn method with crossed affinity immunoelectrophoresis autoradiography method for the measurement of alpha-fetoprotein variant (AFP-L3) in differentiation of benign and malignant liver.
  • METHODS: Serum AFP-L3 variants in 102 primary hepatocellular carcinoma patients and 41 chronic and cirrhosis patients were separated by microcentrifugalcolumn method and crossed affinity immunoelectrophoresis autoradiography method and the clinical value of both method were compared.
  • RESULTS: In 102 primary hepatocellular carcinoma patients, the sensitivity of AFP-L3 was 79.4% and 91.2% respectively, in 41 chronic and cirrhosis patients.
  • In the 4 primary hepatocellular carcinoma patients with lower AFP-L3, the AFP-L3 was positive by useing microcentrifugalcolumn method, but none of AFP-L3 were found by useing crossed affinity immunoelectrophoresis autoradiography method.
  • CONCLUSION: The micro centrifugalcolumn method is more simple and rapid, it may be more useful in differentiation of benign and malignant liver than traditional crossed affinity immunoelectrophoresis autoradiography method.
  • [MeSH-minor] Adult. Aged. Carcinoma, Hepatocellular / chemistry. Female. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19469181.001).
  • [ISSN] 1003-9279
  • [Journal-full-title] Zhonghua shi yan he lin chuang bing du xue za zhi = Zhonghua shiyan he linchuang bingduxue zazhi = Chinese journal of experimental and clinical virology
  • [ISO-abbreviation] Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Protein Isoforms; 0 / alpha-Fetoproteins
  •  go-up   go-down


18. Yang ZX, Wang D, Wang G, Zhang QH, Liu JM, Peng P, Liu XH: Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma. J Cancer Res Clin Oncol; 2010 Apr;136(4):625-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical study of recombinant adenovirus-p53 combined with fractionated stereotactic radiotherapy for hepatocellular carcinoma.
  • OBJECTIVE: The purpose of our study was to evaluate the feasibility and treatment outcomes of recombinant adenovirus-p53 (rAd-p53, trademarked as Gendicine) combined with fractionated stereotactic radiotherapy (fSRT) in treatment of primary hepatocellular carcinoma (HCC).
  • CONCLUSION: These results suggest that rAd-p53 combined with fSRT is a relatively safe and effective method for treating primary hepatocellular carcinoma compared with only fSRT.
  • Thus, rAd-p53 combined with fractionated SRT may be preferred as a choice of local treatment for primary HCC when the patients are inoperable or when the patients refuse operation.
  • [MeSH-major] Adenoviridae / genetics. Carcinoma, Hepatocellular / therapy. Genes, p53. Genetic Therapy. Liver Neoplasms / therapy. Radiosurgery
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cardiovasc Intervent Radiol. 2006 Jan-Feb;29(1):39-48 [16328697.001]
  • [Cites] Radiother Oncol. 2004 May;71(2):139-46 [15110446.001]
  • [Cites] Br J Radiol. 2007 Mar;80(951):194-201 [17038412.001]
  • [Cites] Acta Oncol. 2006;45(7):838-47 [16982548.001]
  • [Cites] Curr Pharm Biotechnol. 2007 Dec;8(6):332-6 [18289041.001]
  • [Cites] Jpn J Cancer Res. 2000 Oct;91(10):1044-50 [11050476.001]
  • [Cites] Ann Surg Oncol. 2008 Apr;15(4):1015-24 [18236114.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Acta Oncol. 2006;45(7):831-7 [16982547.001]
  • [Cites] Hepatol Res. 2008 Jan;38(1):60-9 [17506837.001]
  • [Cites] Technol Cancer Res Treat. 2003 Jun;2(3):223-35 [12779353.001]
  • [Cites] Q J Med. 1985 Nov;57(223):705-8 [3001812.001]
  • [Cites] Cancer. 1993 Jan 1;71(1):62-5 [8380123.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Sep 30;94(20):11037-42 [9380755.001]
  • [Cites] J BUON. 2007 Sep;12 Suppl 1:S9-12 [17935284.001]
  • [Cites] Monaldi Arch Chest Dis. 2003 Oct-Dec;59(4):287-95 [15148838.001]
  • [Cites] Rays. 2003 Jul-Sep;28(3):299-302 [15018317.001]
  • (PMID = 19882171.001).
  • [ISSN] 1432-1335
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


19. Qiu XQ, Tan SK, Yu HP, Zeng XY, Li LQ, Hu L: [Synergistic effect of HBV infection, alcohol and raw fish consumption on oncogenisis of primary hepatic carcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Feb;30(2):113-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Synergistic effect of HBV infection, alcohol and raw fish consumption on oncogenisis of primary hepatic carcinoma].
  • OBJECTIVE: To study the correlation of eating raw fish with primary hepatic carcinoma (PHC), and to investigate the synergistic effect of HBV infection, alcohol consumption and eating raw fish on the oncogenesis of PHC.
  • CONCLUSION: A history of eating raw fish may be an important risk factor for suffering primary hepatic carcinoma.
  • HBV infection, alcohol consumption and eating raw fish may have a synergistic effect on the developing of primary hepatic carcinoma.
  • [MeSH-major] Alcohol Drinking. Carcinoma, Hepatocellular / etiology. Hepatitis B. Liver Neoplasms / etiology. Seafood
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Case-Control Studies. China / epidemiology. Eating. Female. Fishes. Humans. Logistic Models. Male. Middle Aged. Odds Ratio. Risk Factors. Young Adult

  • MedlinePlus Health Information. consumer health - Alcohol.
  • MedlinePlus Health Information. consumer health - Hepatitis B.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18646693.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


20. Yan K, Chen MH, Yang W, Wang YB, Gao W, Hao CY, Xing BC, Huang XF: Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors. Eur J Radiol; 2008 Aug;67(2):336-47
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of hepatocellular carcinoma: long-term outcome and prognostic factors.
  • PURPOSE: To investigate the efficacy of radiofrequency ablation (RFA) for hepatocellular carcinoma (HCC), and the prognostic factors for post-RFA survival rate.
  • Nine potential factors were found with significant effects on survival rate, and they were number of tumors, location of tumors, pre-RFA liver function enzymes, Child-Pugh classification, AJCC staging, primary or recurrent HCC, tumor pathological grading, using mathematical protocol in RFA procedure and tumor necrosis 1 month after RFA.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Liver Function Tests. Male. Middle Aged. Neoplasm Staging. Prognosis. Proportional Hazards Models. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17765421.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Ireland
  •  go-up   go-down


21. O'Leary JG, Randall H, Onaca N, Jennings L, Klintmalm GB, Davis GL: Post-liver transplant survival in hepatitis C patients is improving over time. Liver Transpl; 2009 Apr;15(4):360-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Post-liver transplant survival in hepatitis C patients is improving over time.
  • Outcomes after orthotopic liver transplantation for chronic hepatitis C have been reported to be worsening over the last 2 decades.
  • We analyzed our center's experience over 15 years to identify trends in post-orthotopic liver transplantation survival in patients with and without hepatitis C virus infection.
  • Patient survival and graft survival among adult primary orthotopic liver transplantation recipients who survived more than 90 days from January 1991 to June 2006 at the Baylor Regional Transplant Institute (n = 1901) were evaluated by Kaplan-Meier analysis.
  • Several factors accounted for this improvement, notably better selection of hepatocellular carcinoma patients and fewer late cytomegalovirus infections.
  • In conclusion, posttransplant survival after orthotopic liver transplantation for chronic hepatitis C has improved significantly over the last 15 years despite demographic changes in patients and grafts that have been previously shown to impair survival.
  • A major reason for this improvement is better selection of patients with concurrent hepatocellular carcinoma and fewer late cytomegalovirus infections, although other factors may play a role as well.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Hepatitis C, Chronic / mortality. Hepatitis C, Chronic / surgery. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Liver Transplantation / mortality

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 AASLD.
  • (PMID = 19326409.001).
  • [ISSN] 1527-6473
  • [Journal-full-title] Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society
  • [ISO-abbreviation] Liver Transpl.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Hu JX, Miao XY, Zhong DW, Dai WD, Liu W: Anterior approach for complete isolated caudate lobectomy. Hepatogastroenterology; 2005 Nov-Dec;52(66):1641-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND/AIMS: Complete isolated caudate lobectomy is a technique-demanding procedure that entails the surgeon's judgement and precise knowledge of liver anatomy.
  • Primary diagnoses included hepatocellular carcinoma, hemangioma and adenoma.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hemostasis, Surgical / methods. Hepatectomy / methods. Liver Neoplasms / surgery. Neoplasm Invasiveness / pathology
  • [MeSH-minor] Adult. Aged. Cohort Studies. Female. Follow-Up Studies. Humans. Intraoperative Care / methods. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Risk Assessment. Sensitivity and Specificity. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334747.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


23. Wu F, Wu L, Zheng S, Ding W, Teng L, Wang Z, Ma Z, Zhao W: The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy. Dig Liver Dis; 2006 Jul;38(7):490-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The clinical value of hepatocyte growth factor and its receptor--c-met for liver cancer patients with hepatectomy.
  • BACKGROUND: To study the dynamic change of hepatocyte growth factor after hepatectomy in patients with primary liver cancer, and to analyse the prognostic value of hepatocyte growth factor and c-met for these patients.
  • METHODS: Thirty-one consecutive patients undergoing partial hepatectomy for liver cancer were studied.
  • RESULTS: Liver cancer patients had a significantly higher level of serum hepatocyte growth factor than normal controls (1.0424+/-0.498 ng/ml versus 0.685+/-0.115 ng/ml, p=0.008).
  • Serum hepatocyte growth factor level was positively affected by tumour size, node cirrhosis, portal vein tumour thrombi, cholangiocarcinoma (including combined hepatocellular carcinoma), poorly differentiated hepatocellular carcinoma and tumour recurrence or metastases.
  • CONCLUSION: The over-expressions of the hepatocyte growth factor and c-met indicates an adverse prognosis for patients with liver cancer.
  • Liver regeneration may be a main factor leading to high level of serum hepatocyte growth factor in early postoperative stage.
  • [MeSH-major] Biomarkers, Tumor / blood. Biomarkers, Tumor / metabolism. Hepatectomy. Hepatocyte Growth Factor / blood. Liver Neoplasms / diagnosis. Liver Neoplasms / metabolism. Proto-Oncogene Proteins c-met / metabolism
  • [MeSH-minor] Adult. Aged. Female. Gene Expression Regulation, Neoplastic. Humans. Male. Middle Aged. RNA, Messenger / genetics

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16627020.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 67256-21-7 / Hepatocyte Growth Factor; EC 2.7.10.1 / Proto-Oncogene Proteins c-met
  •  go-up   go-down


24. Kwon JE, Kim SH, Cho NH: No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma. Int J Gynecol Cancer; 2006 Jul-Aug;16(4):1691-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] No ancillary finding is valid to distinguish a primary ovarian hepatoid carcinoma from metastatic hepatocellular carcinoma.
  • Primary ovarian hepatoid carcinomas (POHC) are extremely rare.
  • Especially rare are those with phenotypic properties of hepatocellular carcinoma (HCC) and an absence of clinical evidence of hepatic tumor.
  • We report a case of a POHC with a common microscopic, immunophenotypic, and ultrastructural property of HCC in the absence of a liver mass.
  • [MeSH-major] Carcinoma, Hepatocellular / diagnosis. Liver Neoplasms / diagnosis. Ovarian Neoplasms / diagnosis
  • [MeSH-minor] Adult. Diagnosis, Differential. Female. Humans. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16884387.001).
  • [ISSN] 1048-891X
  • [Journal-full-title] International journal of gynecological cancer : official journal of the International Gynecological Cancer Society
  • [ISO-abbreviation] Int. J. Gynecol. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


25. Yan K, Wang YB, Chen MH, Gao W, Yang W, Dai Y, Yin SS: [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors]. Zhonghua Yi Xue Za Zhi; 2005 Aug 31;85(33):2322-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factors on outcome of radiofrequency ablation of 172 primary hepatic tumors].
  • OBJECTIVE: To investigate the prognostic factors affecting outcome in Radiofrequency (RF) ablation of primary hepatic tumors by univariate and multivariate analyses, and to assess the therapeutic efficacy of Radio-frequency ablation.
  • METHODS: A total of 172 patients with primary hepatic tumors underwent RF treatment in our department between 1999 and 2004.
  • For 116 patients who underwent RF when first diagnosis, the survival rates in patients with different tumor stage (UICC standard of hepatocellular carcinoma) at half a year, 1 year, 2 year and 3 year were estimated as follows: 96.7%, 92.3%, 81.6% and 65.3% in 33 patients of stage I-II; 91.2%, 76.3%, 56.6% and 51.4% in 83 patients of stage III-IV; There was significant difference in survival rates between patients of stage I-II and patients of stage III-IV.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Multivariate Analysis. Prognosis. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16321224.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


26. Jin ZH, Yang RJ, Dong B, Xing BC: Progenitor gene DLK1 might be an independent prognostic factor of liver cancer. Expert Opin Biol Ther; 2008 Apr;8(4):371-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progenitor gene DLK1 might be an independent prognostic factor of liver cancer.
  • BACKGROUND: Delta-like 1 homolog (DLK1) is a marker for progenitor cells of the liver.
  • The gene encoding DLK1 is expressed early during embryonic development but, importantly, it is also expressed in some human liver cancers.
  • OBJECTIVES: To examine the association between the DLK1 gene and survival time and whether high levels of expression of DLK1 are a prognostic factor for liver cancer.
  • METHODS: We evaluated 60 cases of primary liver cancer, and investigated the link between the expression of DLK1 and patient survival.
  • [MeSH-major] Bile Duct Neoplasms / chemistry. Bile Ducts, Intrahepatic / chemistry. Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / chemistry. Cholangiocarcinoma / chemistry. Intercellular Signaling Peptides and Proteins / analysis. Liver Neoplasms / chemistry. Membrane Proteins / analysis. Neoplastic Stem Cells / chemistry
  • [MeSH-minor] Adult. Aged. Blotting, Western. Gene Expression Regulation, Neoplastic. Humans. Immunohistochemistry. Kaplan-Meier Estimate. Middle Aged. Prognosis. Proportional Hazards Models. Reverse Transcriptase Polymerase Chain Reaction. Risk Assessment. Risk Factors

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18352842.001).
  • [ISSN] 1744-7682
  • [Journal-full-title] Expert opinion on biological therapy
  • [ISO-abbreviation] Expert Opin Biol Ther
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DLK1 protein, human; 0 / Intercellular Signaling Peptides and Proteins; 0 / Membrane Proteins
  •  go-up   go-down


27. Kim KH, Lee SG, Park EH, Hwang S, Ahn CS, Moon DB, Ha TY, Song GW, Jung DH, Kim KM, Lim YS, Lee HC, Chung YH, Lee YS, Suh DJ: Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma. Ann Surg Oncol; 2009 Mar;16(3):623-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatments and prognoses of patients with combined hepatocellular carcinoma and cholangiocarcinoma.
  • BACKGROUND: Combined hepatocellular carcinoma and cholangiocarcinoma is a very rare form of primary liver cancer containing components of both tumor types.
  • PATIENTS AND METHODS: Of the 2427 patients who underwent hepatectomy or liver transplantation because of a primary hepatic malignancy from January 1989 to July 2006 at the Asan Medical Center, Seoul, Korea, 29 had hepatocellular carcinoma and cholangiocarcinoma as a single mixed or transitional tumor.
  • CONCLUSIONS: Patients with combined hepatocellular carcinoma and cholangiocarcinoma had poor postoperative survival rates.
  • [MeSH-major] Bile Duct Neoplasms / surgery. Bile Ducts, Intrahepatic / surgery. Carcinoma, Hepatocellular / surgery. Cholangiocarcinoma / surgery. Liver Neoplasms / surgery. Neoplasms, Multiple Primary / surgery
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Hepatectomy. Humans. Liver Transplantation. Lymph Nodes / pathology. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / surgery. Neoplasm Staging. Prognosis. Retrospective Studies. Risk Factors. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19130133.001).
  • [ISSN] 1534-4681
  • [Journal-full-title] Annals of surgical oncology
  • [ISO-abbreviation] Ann. Surg. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


28. Bernal P, Raoul JL, Stare J, Sereegotov E, Sundram FX, Kumar A, Jeong JM, Pusuwan P, Divgi C, Zanzonico P, Vidmar G, Buscombe J, Chau TT, Saw MM, Chen S, Ogbac R, Dondi M, Padhy AK: International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study. Semin Nucl Med; 2008 Mar;38(2):S40-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] International Atomic Energy Agency-sponsored multination study of intra-arterial rhenium-188-labeled lipiodol in the treatment of inoperable hepatocellular carcinoma: results with special emphasis on prognostic value of dosimetric study.
  • A multicenter study was sponsored by the International Atomic Energy Agency (IAEA) to assess the safety and efficacy of transarterial rhenium-188 ((188)Re) HDD lipiodol (radioconjugate to lipiodol using an HDD kit) in the treatment of unresectable hepatocellular carcinoma.
  • This multicenter study shows that (188)Re lipiodol is a safe and cost-effective method to treat primary hepatocellular carcinoma via the transarterial route and requires further evaluation by treatment of greater numbers of patients.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Iodized Oil / administration & dosage. Liver Neoplasms / radiotherapy. Radioisotopes / administration & dosage. Rhenium / administration & dosage
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Injections, Intra-Arterial. International Agencies. Male. Middle Aged. Nuclear Energy. Prognosis. Radiotherapy Planning, Computer-Assisted

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18243842.001).
  • [ISSN] 0001-2998
  • [Journal-full-title] Seminars in nuclear medicine
  • [ISO-abbreviation] Semin Nucl Med
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Radioisotopes; 7440-15-5 / Rhenium; 8001-40-9 / Iodized Oil
  •  go-up   go-down


29. Geyik S, Akhan O, Abbasoğlu O, Akinci D, Ozkan OS, Hamaloğlu E, Ozmen M: Radiofrequency ablation of unresectable hepatic tumors. Diagn Interv Radiol; 2006 Dec;12(4):195-200
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • PURPOSE: To evaluate the efficacy and safety of radiofrequency ablation (RFA) in the treatment of primary and metastatic liver malignancies.
  • MATERIALS AND METHODS: Twenty-nine consecutive patients who have primary (n=9) and metastatic (n=20) liver malignancies were treated with RFA.
  • Primary tumors that gave rise to metastatic lesion were all colorectal cancer except one with gallbladder carcinoma.
  • RESULTS: In the hepatocellular carcinoma (HCC) group, 1 patient was lost to follow-up, 5 deceased due to extensive disease, and 3 are still on the follow-up.
  • In the metastatic liver disease group, 8 patients died due to progression of disease, 1 deceased due to stroke, and 3 were lost to follow-up.
  • Recurrence occurred in 7 lesions (7/70) of 4 patients (4/20) in the metastatic liver disease group.
  • CONCLUSION: RFA of primary and metastatic liver malignancies is a safe and effective tool for local control of disease in unresectable hepatic malignancies.
  • [MeSH-major] Catheter Ablation / utilization. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / epidemiology. Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / radiography. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local / epidemiology. Neoplasm Recurrence, Local / etiology. Neoplasm Recurrence, Local / pathology. Neoplasm Recurrence, Local / radiography. Outcome Assessment (Health Care). Postoperative Complications. Retrospective Studies. Severity of Illness Index. Tomography, X-Ray Computed. Turkey / epidemiology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17160805.001).
  • [ISSN] 1305-3825
  • [Journal-full-title] Diagnostic and interventional radiology (Ankara, Turkey)
  • [ISO-abbreviation] Diagn Interv Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Turkey
  •  go-up   go-down


30. Malik SM, Gupte PA, de Vera ME, Ahmad J: Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma. Clin Gastroenterol Hepatol; 2009 Jul;7(7):800-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation in patients with nonalcoholic steatohepatitis-related hepatocellular carcinoma.
  • BACKGROUND & AIMS: The increasing incidence of hepatocellular carcinoma in the United States is only partially accounted for by hepatitis C virus (HCV) infections.
  • The prevalence of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis (NASH) is not known; guidelines from the American Association for the Study of Liver Diseases do not recommend surveillance imaging.
  • We sought to determine the prevalence of hepatocellular carcinoma among patients undergoing liver transplantation for NASH-related cirrhosis and their outcome after surgery, compared with controls.
  • METHODS: We reviewed the records of adult patients with NASH cirrhosis who underwent liver transplantation by using a prospectively collected database from a single center.
  • Data from patients with NASH cirrhosis were compared with matched controls who received transplantation for primary biliary cirrhosis/primary sclerosing cholangitis, alcoholic liver disease, or HCV.
  • RESULTS: Seventeen of 98 patients (17%) with NASH cirrhosis were diagnosed with hepatocellular carcinoma.
  • Six patients were diagnosed with hepatocellular carcinoma incidentally on explant.
  • Survival after liver transplantation was 88% after mean follow-up of 2.5 years.
  • The number of NASH patients known to have hepatocellular carcinoma before liver transplantation was greater than the number of patients with primary biliary cirrhosis/primary sclerosing cholangitis and comparable to the number of patients with alcoholic liver disease and HCV.
  • CONCLUSIONS: Patients with NASH cirrhosis are at risk for developing hepatocellular carcinoma; patients with NASH cirrhosis, especially men older than 50 years, should undergo surveillance imaging.
  • Patients with NASH and hepatocellular carcinoma have good outcomes after liver transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / surgery. Fatty Liver / complications. Fatty Liver / epidemiology. Liver Transplantation
  • [MeSH-minor] Adult. Age Factors. Aged. Case-Control Studies. Female. Humans. Male. Middle Aged. Risk Factors. Sex Factors. Survival Analysis. Treatment Outcome. United States

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Liver Transpl. 2009 Oct;15(10):1367-8 [19806686.001]
  • (PMID = 19281869.001).
  • [ISSN] 1542-7714
  • [Journal-full-title] Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association
  • [ISO-abbreviation] Clin. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. Burroughs AK, Sabin CA, Rolles K, Delvart V, Karam V, Buckels J, O'Grady JG, Castaing D, Klempnauer J, Jamieson N, Neuhaus P, Lerut J, de Ville de Goyet J, Pollard S, Salizzoni M, Rogiers X, Muhlbacher F, Garcia Valdecasas JC, Broelsch C, Jaeck D, Berenguer J, Gonzalez EM, Adam R, European Liver Transplant Association: 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome. Lancet; 2006 Jan 21;367(9506):225-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] 3-month and 12-month mortality after first liver transplant in adults in Europe: predictive models for outcome.
  • BACKGROUND: Mortality after liver transplantation depends on heterogeneous recipient and donor factors.
  • Our aim was to assess risk of death and to develop models to help predict mortality after liver transplantation.
  • METHODS: We analysed data from 34,664 first adult liver transplants from the European Liver Transplant Registry to identify factors associated with mortality at 3-months (n=21,605 in training dataset) and 12-months (n=18,852 in training dataset) after transplantation.
  • Increased mortality at 3-months post-transplantation was associated with acute liver failure (adjusted odds ratio 1.61), donor age older than 60 years (1.16), compatible (1.22) or incompatible (2.07) donor-recipient blood group, older recipient age (1.12 per 5 years), split or reduced graft (1.96), total ischaemia time of longer than 13 h (1.38), and low United Network for Organ Sharing score (score 1: 2.43; score 2: 1.67).
  • However, cirrhosis with hepatocellular carcinoma, alcohol cirrhosis, hepatitis C or primary biliary cirrhosis, donor age 40 years or younger, or less, hepatitis B, and larger size of transplant centre (> or = 70 transplants per year) were associated with improved early outcomes.
  • [MeSH-major] Cause of Death. Liver Failure / surgery. Liver Transplantation / statistics & numerical data. Logistic Models
  • [MeSH-minor] Adult. Aged. Europe. Female. Humans. Male. Middle Aged. Postoperative Period. Predictive Value of Tests. Registries. Time Factors

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Lancet. 2006 Jun 3;367(9525):1816; author reply 1816-7 [16753479.001]
  • (PMID = 16427491.001).
  • [ISSN] 1474-547X
  • [Journal-full-title] Lancet (London, England)
  • [ISO-abbreviation] Lancet
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


32. Kim H, Oh BK, Roncalli M, Park C, Yoon SM, Yoo JE, Park YN: Large liver cell change in hepatitis B virus-related liver cirrhosis. Hepatology; 2009 Sep;50(3):752-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Large liver cell change in hepatitis B virus-related liver cirrhosis.
  • Large liver cell change (LLCC) refers to microscopic lesions often found in various chronic liver diseases; however, its nature is still controversial.
  • Thirty-four formalin-fixed and 19 fresh frozen hepatitis B virus (HBV)-related cirrhosis samples were examined for the presence of LLCC, small liver cell change (SLCC), and hepatocellular carcinoma (HCC).
  • The cell cycle checkpoint status (p21, p27, p16, Tp53), cell dynamics (proliferating cell nuclear antigen, Ki-67, terminal deoxynucleotidyl transferase-mediated dUTP-biotin nick-end labeling, M30), DNA damage (gamma-H2AX [H2A histone family, member X]), telomere lengths, chromosomal instability (micronuclei index), and senescence-associated beta-galactosidase (SA-beta-Gal) activity were evaluated using an in situ approach and compared to those in normal liver (n = 5) and liver with chronic cholestasis (34 cases of hepatolithiasis and three cases of primary biliary cirrhosis).
  • In HBV-related cirrhosis, the p21, p27, and p16 cell cycle checkpoint markers were activated in normal-looking cirrhotic hepatocytes (NLCH), but diminished gradually from LLCC, SLCC, to HCC, with an increase in Tp53 expression.
  • In contrast, cholestatic LLCC showed retained expression of cell cycle checkpoint markers and decreased net cellular gain compared to adjacent normal-looking hepatocytes.
  • The characteristics of HBV-related LLCC are more consistent with dysplastic rather than merely reactive hepatocytes, whereas cholestatic LLCC more likely represents reactive change with more stringent cell cycle checkpoint control.
  • [MeSH-major] Hepatitis B, Chronic / pathology. Liver Cirrhosis / pathology
  • [MeSH-minor] Adult. Aged. Apoptosis. Carcinoma, Hepatocellular / pathology. Cell Aging / physiology. Cell Cycle. Cell Proliferation. Cholestasis, Intrahepatic / metabolism. Cholestasis, Intrahepatic / pathology. Chromosomal Instability. DNA Damage. Female. Humans. Immunohistochemistry. In Situ Nick-End Labeling. Liver Neoplasms / pathology. Middle Aged. Telomere / chemistry. beta-Galactosidase / analysis

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19585549.001).
  • [ISSN] 1527-3350
  • [Journal-full-title] Hepatology (Baltimore, Md.)
  • [ISO-abbreviation] Hepatology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] EC 3.2.1.23 / beta-Galactosidase
  •  go-up   go-down


33. Liang SX, Jiang GL, Zhu XD, Fu XL, Li FX, Huang QF, Wang AY, Chen L, Lu HJ: [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy]. Zhonghua Zhong Liu Za Zhi; 2005 Oct;27(10):613-5
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prognostic factor of primary liver cancer treated by hypofractionated three-dimensional conformal radiotherapy].
  • OBJECTIVE: To evaluate the toxicity and efficacy of primary liver cancer (PLC) treated by hypofractionated three-dimensional conformal radiotherapy (3DCRT) and investigate the prognostic factors.
  • 108 patients had Child-Pugh Grade A liver cirrhosis and 20 Child-Pugh Grade B liver cirrhosis.
  • CONCLUSION: T stage, GTV, PVTT and Child-Pugh Grade have significant impact on the overall survival in primary liver cancer patients treated by three-dimensional conformal radiotherapy.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Conformal / methods
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Imaging, Three-Dimensional. Male. Middle Aged. Prognosis. Regression Analysis. Retrospective Studies

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16438872.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


34. Sugahara S, Nakayama H, Fukuda K, Mizumoto M, Tokita M, Abei M, Shoda J, Matsuzaki Y, Thono E, Tsuboi K, Tokuuye K: Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis. Strahlenther Onkol; 2009 Dec;185(12):782-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Proton-beam therapy for hepatocellular carcinoma associated with portal vein tumor thrombosis.
  • BACKGROUND AND PURPOSE: The prognosis of patients with advanced hepatocellular carcinoma (HCC) with portal vein tumor thrombosis (PVTT) is extremely poor, as effective treatment options are limited.
  • A median total dose of 72.6 GyE in 22 fractions was delivered over 31 days to a target volume that encompassed both the primary hepatic lesion and the PVTT.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Liver Neoplasms / radiotherapy. Neoplastic Cells, Circulating / radiation effects. Portal Vein / radiation effects. Protons / therapeutic use
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Disease Progression. Disease-Free Survival. Dose Fractionation. Female. Follow-Up Studies. Humans. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiation Injuries / etiology. Radiotherapy Dosage. Radiotherapy Planning, Computer-Assisted. Radiotherapy, Adjuvant. Retrospective Studies. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Portal thrombosis.
  • Genetic Alliance. consumer health - Portal vein thrombosis.
  • Genetic Alliance. consumer health - Thrombosis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Hepatogastroenterology. 2000 Mar-Apr;47(32):507-11 [10791223.001]
  • [Cites] Jpn J Clin Oncol. 2006 Feb;36(2):93-9 [16517834.001]
  • [Cites] Hepatology. 2000 Dec;32(6):1224-9 [11093728.001]
  • [Cites] Hepatology. 1999 Jan;29(1):62-7 [9862851.001]
  • [Cites] Hepatology. 2000 Aug;32(2):233-8 [10915729.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):231-4 [19370425.001]
  • [Cites] Cancer. 1997 Jun 1;79(11):2087-94 [9179054.001]
  • [Cites] World J Gastroenterol. 2005 Dec 14;11(46):7237-41 [16437621.001]
  • [Cites] Lancet. 1985 Mar 16;1(8429):595-9 [2857944.001]
  • [Cites] Cancer. 2002 Aug 1;95(3):588-95 [12209752.001]
  • [Cites] Strahlenther Onkol. 2007 Aug;183(8):411-6 [17680219.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):598-604 [19016019.001]
  • [Cites] Nihon Igaku Hoshasen Gakkai Zasshi. 1983 Jun;43(6):781-93 [6314247.001]
  • [Cites] Strahlenther Onkol. 2008 Jun;184(6):302-6 [18535805.001]
  • [Cites] J Gastroenterol. 2005 Mar;40(3):225-35 [15830281.001]
  • [Cites] Q J Med. 1985 Nov;57(223):705-8 [3001812.001]
  • [Cites] Ann Surg. 1998 Mar;227(3):433-9 [9527067.001]
  • [Cites] Br J Cancer. 2005 Sep 5;93(5):557-64 [16106266.001]
  • [Cites] Cancer. 2005 Aug 15;104(4):794-801 [15981284.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Am J Clin Oncol. 2002 Apr;25(2):189-93 [11943901.001]
  • [Cites] Lancet. 1992 Nov 28;340(8831):1358 [1360077.001]
  • [Cites] Arch Pathol. 1973 Jul;96(1):21-6 [4708001.001]
  • [Cites] Best Pract Res Clin Gastroenterol. 2005 Feb;19(1):3-23 [15757802.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Feb 1;61(2):432-43 [15667964.001]
  • [Cites] Strahlenther Onkol. 2007 Dec;183(12):685-8 [18040613.001]
  • [Cites] Cancer. 1981 Jan 1;47(1):207-14 [7459811.001]
  • [Cites] Am J Clin Oncol. 1998 Aug;21(4):386-91 [9708639.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1341-6 [7713792.001]
  • [Cites] Jpn J Clin Oncol. 2000 Jul;30(7):318-21 [11007166.001]
  • [Cites] Cancer. 2006 May 1;106(9):1990-7 [16565970.001]
  • [Cites] Surgery. 1990 Nov;108(5):821-7 [2173162.001]
  • [Cites] Hepatogastroenterology. 2004 Mar-Apr;51(56):510-4 [15086193.001]
  • [Cites] Strahlenther Onkol. 2008 Nov;184(11):586-91 [19016017.001]
  • [Cites] Semin Liver Dis. 1999;19(3):271-85 [10518307.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Winter;3(1):8-24 [12684589.001]
  • [Cites] Am J Roentgenol Radium Ther Nucl Med. 1973 Jan;117(1):73-80 [4685535.001]
  • [Cites] J Surg Oncol. 2002 Jul;80(3):143-8 [12115797.001]
  • [Cites] Strahlenther Onkol. 2009 Apr;185(4):211-21 [19370423.001]
  • [Cites] Cancer. 1988 May 15;61(10):1983-7 [2834036.001]
  • (PMID = 20013087.001).
  • [ISSN] 1439-099X
  • [Journal-full-title] Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al]
  • [ISO-abbreviation] Strahlenther Onkol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Protons
  •  go-up   go-down


35. Perz JF, Armstrong GL, Farrington LA, Hutin YJ, Bell BP: The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol; 2006 Oct;45(4):529-38
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide.
  • BACKGROUND/AIMS: End-stage liver disease accounts for one in forty deaths worldwide.
  • Chronic infections with hepatitis B virus (HBV) and hepatitis C virus (HCV) are well-recognized risk factors for cirrhosis and liver cancer, but estimates of their contributions to worldwide disease burden have been lacking.
  • METHODS: The prevalence of serologic markers of HBV and HCV infections among patients diagnosed with cirrhosis or hepatocellular carcinoma (HCC) was obtained from representative samples of published reports.
  • Applied to 2002 worldwide mortality estimates, these fractions represent 929,000 deaths due to chronic HBV and HCV infections, including 446,000 cirrhosis deaths (HBV: n=235,000; HCV: n=211,000) and 483,000 liver cancer deaths (HBV: n=328,000; HCV: n=155,000).
  • CONCLUSIONS: HBV and HCV infections account for the majority of cirrhosis and primary liver cancer throughout most of the world, highlighting the need for programs to prevent new infections and provide medical management and treatment for those already infected.
  • [MeSH-major] Global Health. Hepatitis B, Chronic / mortality. Hepatitis C, Chronic / mortality. Liver Cirrhosis / mortality. Liver Neoplasms / mortality
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Prevalence. Risk Factors. World Health Organization


36. Yang JM, Tong Y, Xie F, Xu F, Kan T, Shen WF, Wu MC: [Study of bloodless hepatectomy under occlusion of total hemi-hepatic vessel]. Zhonghua Wai Ke Za Zhi; 2007 Feb 1;45(3):186-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: Twenty-eight patients with primary liver cancer were divided into two groups of hepatectomy with total hemi-hepatic vascular exclusion (group A) and total hepatic inflow occlusion (group B).
  • The time of hepatic vascular control, intraoperative blood loss, volume of removed liver, postoperative liver function recovery and complications were compared between the two groups.
  • While the time of hepatic vascular control and volume of lost liver were no difference between the groups (P>0.05).
  • CONCLUSIONS: Intraoperative blood loss and liver damage of hepatectomy under the total hemi-hepatic vascular exclusion could be less than that under the other methods of vascular occlusion.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Blood Loss, Surgical / prevention & control. Female. Humans. Liver / blood supply. Liver / surgery. Male. Middle Aged. Regional Blood Flow. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498379.001).
  • [ISSN] 0529-5815
  • [Journal-full-title] Zhonghua wai ke za zhi [Chinese journal of surgery]
  • [ISO-abbreviation] Zhonghua Wai Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


37. Abbasi A, Butt N, Bhutto AR, Gulzar K, Munir SM: Hepatocellular carcinoma: a clinicopathological study. J Coll Physicians Surg Pak; 2010 Aug;20(8):510-3
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatocellular carcinoma: a clinicopathological study.
  • OBJECTIVE: To describe the clinico-pathological and radiological profile of hepatocellular carcinoma.
  • METHODOLOGY: All consecutive patients suspected of having hepatocellular carcinoma (HCC), were admitted and included in this study.
  • Patients with primary carcinoma elsewhere in the body, metastatic in the liver, fibrolamellar carcinoma and benign tumours were excluded from the study.
  • RESULTS: There were 82 patients with hepatocellular carcinoma including 58 males and 24 females, with male to female ratio of 2.8:1.
  • Tumour size was larger than 50% of liver size in 42 (51.2%) with portal vein thrombosis in 10 (12.19%).
  • According to Okuda staging system 18 patients had stage 1, 50 had stage 2 and 14 had stage 3 hepatocellular carcinoma.
  • CONCLUSION: The mean age of presentation of hepatocellular carcinoma was younger as compared to western countries with potentially large non-resectable lesions.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Hepatitis B, Chronic / complications. Hepatitis C, Chronic / complications. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20688014.001).
  • [ISSN] 1022-386X
  • [Journal-full-title] Journal of the College of Physicians and Surgeons--Pakistan : JCPSP
  • [ISO-abbreviation] J Coll Physicians Surg Pak
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Pakistan
  •  go-up   go-down


38. Zhou Q, Zhu XQ, Zhang J, Xu ZL, Lu P, Wu F: Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment. Ultrasound Med Biol; 2008 Jan;34(1):81-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • All patients received one-session HIFU treatment for primary cancer, including complete ablation in eight patients without metastasis, and partial ablation in seven patients with metastases.
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / immunology. Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / therapy. Female. Humans. Interleukin-10 / blood. Interleukin-6 / blood. Liver Neoplasms / immunology. Liver Neoplasms / pathology. Liver Neoplasms / secondary. Liver Neoplasms / therapy. Male. Middle Aged. Neoplasm Metastasis. Transforming Growth Factor beta1 / blood. Transforming Growth Factor beta2 / blood. Vascular Endothelial Growth Factor A / blood

  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17854983.001).
  • [ISSN] 0301-5629
  • [Journal-full-title] Ultrasound in medicine & biology
  • [ISO-abbreviation] Ultrasound Med Biol
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Cytokines; 0 / Interleukin-6; 0 / Transforming Growth Factor beta1; 0 / Transforming Growth Factor beta2; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A; 130068-27-8 / Interleukin-10
  •  go-up   go-down


39. Ikeguchi M, Iwamoto A, Taniguchi K, Katano K, Hirooka Y: The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma. J Exp Clin Cancer Res; 2005 Sep;24(3):415-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The gene expression level of transforming growth factor-beta (TGF-beta) as a biological prognostic marker of hepatocellular carcinoma.
  • The question that transforming growth factor-beta (TGF-beta) provides a tumor-suppressive or a tumor promoting role is still unknown in hepatocellular carcinoma (HCC).
  • In the present study, we quantitatively investigated the gene expression levels of TGF-beta in liver tissues from patients with HCC.
  • A total of 59 patients with primary HCC who underwent hepatectomy between 1993 and 2001 were enrolled.
  • The relative expression level of TGF-beta mRNA of 59 tumor tissues did not differ from those of 8 normal liver tissues or 59 noncancerous liver tissues.
  • [MeSH-major] Biomarkers, Tumor / genetics. Carcinoma, Hepatocellular / genetics. Gene Expression. Liver Neoplasms / genetics. Transforming Growth Factors / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Immunohistochemistry. Liver / metabolism. Male. Middle Aged. Prognosis. RNA, Messenger / genetics. Reverse Transcriptase Polymerase Chain Reaction. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16270528.001).
  • [ISSN] 0392-9078
  • [Journal-full-title] Journal of experimental & clinical cancer research : CR
  • [ISO-abbreviation] J. Exp. Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Italy
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / RNA, Messenger; 76057-06-2 / Transforming Growth Factors
  •  go-up   go-down


40. Dong-Dong L: Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro. Hepatogastroenterology; 2005 Jul-Aug;52(64):1186-90
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Up-regulation expression of MLC1 in human liver cancer tissue and enhanced SMMC7721 cell tumorigenesis in vivo and vitro.
  • BACKGROUND/AIMS: We screened a novel gene MLC1 in human liver cancer tissue by differential display, and its cDNA full-length is 1600bp.
  • The purpose of this study is to find expression of MLC1 gene in human liver cancer tissue and the affect to SMMC7721 cell tumorigenesis in vivo and vitro.
  • METHODOLOGY: 250 cases of primary HCC tissue samples were studied for MLC1 mRNA and protein expression using RT-PCR, western blot, immunohistochemistry, MLC1 stable transfection into SMMC771, and SMMC7721 cells growth curve was analyzed by MTT method and SMMC7721 cells tumorigenesis in vivo.
  • CONCLUSIONS: MLC1 gene showed up-regulation expression at both the mRNA and protein levels in HCC tissues and that MLC1 plays an important role in the growth of hepatoma cell SMMC7721 in vitro and vivo.
  • [MeSH-major] Carcinoma, Hepatocellular / etiology. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / etiology. Liver Neoplasms / metabolism. Membrane Proteins / metabolism
  • [MeSH-minor] Adult. Animals. Cell Culture Techniques. Cell Line, Tumor. Female. Humans. Male. Mice. Mice, Inbred BALB C. Middle Aged. RNA, Messenger / metabolism. Transfection. Up-Regulation

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16001658.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / MLC1 protein, human; 0 / Membrane Proteins; 0 / Mlc1 protein, mouse; 0 / RNA, Messenger
  •  go-up   go-down


41. Wakasa T, Wakasa K, Shutou T, Hai S, Kubo S, Hirohashi K, Umeshita K, Monden M: A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma. Hepatogastroenterology; 2007 Mar;54(74):508-13
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A histopathological study on combined hepatocellular and cholangiocarcinoma: cholangiocarcinoma component is originated from hepatocellular carcinoma.
  • BACKGROUND/AIMS: Combined hepatocellular and cholangiocarcinoma of the liver is relatively infrequent, and its pathogenesis remains obscure.
  • METHODOLOGY: In this study, we investigated the histopathological features, Ki-67 labeling index, and p53 immunohistochemistry of 18 surgically resected cases of combined hepatocellular and cholangiocarcinoma among 1102 consecutive cases of surgically resected primary liver cancers.
  • Microscopically, we classified the cases into the following three categories according to the arrangement of the hepatocellular carcinoma and cholangiocarcinoma components;.
  • (1) Type I in which hepatocellular carcinoma and cholangiocarcinoma formed nodules that could easily be distinguished from each other, (2) Type II in which the both components were finely mixed, so that the two components were almost indistinguishable, and (3) Type III in which the tumors had lobular structures with hepatocellular carcinomas existing centrally and cholangiocarcinomas existing peripherally.
  • In one case of type I, well differentiated hepatocellular carcinoma demonstrated cholangiocarcinoma in "nodules-in-nodules" fashion.
  • The average of Ki-67 labeling index of hepatocellular carcinoma component of combined hepatocellular and cholangiocarcinoma was 4.4 +/- 3.4% and the index of cholangiocarcinoma component was 11.0 +/- 8.5%, which is significantly higher than that of the hepatocellular carcinoma component.
  • In one case, the cholangiocarcinoma component was positive for p53, but the hepatocellular carcinoma component was negative.
  • In the other 4 cases, both the hepatocellular carcinoma and cholangiocarcinoma components were positive.
  • Metaplasia of hepatocellular carcinoma to intrahepatic cholangiocarcinoma is assumed to be one of the pathogenic pathways of combined hepatocellular and cholangiocarcinoma.
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Neoplasms, Multiple Primary / pathology
  • [MeSH-minor] Adult. Aged. Cell Division / physiology. Cell Transformation, Neoplastic / pathology. Female. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Humans. Immunoenzyme Techniques. Ki-67 Antigen / analysis. Liver / pathology. Male. Metaplasia. Middle Aged. Tumor Suppressor Protein p53 / analysis

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17523309.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Ki-67 Antigen; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


42. Lau PP, Tint KA, Tse GM, Lui PC: Primary hepatic carcinoid tumours: report of two cases. Pathology; 2006 Oct;38(5):458-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary hepatic carcinoid tumours: report of two cases.
  • [MeSH-major] Carcinoid Tumor / pathology. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Biomarkers / analysis. Biomarkers, Tumor / analysis. Carcinoma, Hepatocellular / diagnosis. Chromogranin A / analysis. Cytoplasmic Granules / ultrastructure. Diagnosis, Differential. Female. Hemangioma / diagnosis. Humans. Immunohistochemistry. Keratins / analysis. Male. Synaptophysin / analysis. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17008291.001).
  • [ISSN] 0031-3025
  • [Journal-full-title] Pathology
  • [ISO-abbreviation] Pathology
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / CAM 5.2 antigen; 0 / Chromogranin A; 0 / Synaptophysin; 68238-35-7 / Keratins
  •  go-up   go-down


43. Wang J, Qin Y, Li B, Sun Z, Yang B: Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients. Clin Biochem; 2006 Apr;39(4):344-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of aberrant promoter methylation of GSTP1 in the tumor and serum of Chinese human primary hepatocellular carcinoma patients.
  • To explore the aberrant promoter CpG island methylation of the GSTP1 gene as a biomarker for screening hepatocellular carcinoma (HCC) high risk individuals and for the early detection of HCC, we analyzed its methylation in the tumor and non-tumor tissues and serum samples from 26 patients with HCC, as well as serum from 8 liver cirrhosis patients by methylation-specific PCR (MSP).
  • [MeSH-major] Carcinoma, Hepatocellular / enzymology. DNA Methylation. Glutathione S-Transferase pi / genetics. Liver Neoplasms / enzymology. Promoter Regions, Genetic
  • [MeSH-minor] Adult. Aged. Cell Line, Tumor. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16527261.001).
  • [ISSN] 0009-9120
  • [Journal-full-title] Clinical biochemistry
  • [ISO-abbreviation] Clin. Biochem.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] EC 2.5.1.18 / GSTP1 protein, human; EC 2.5.1.18 / Glutathione S-Transferase pi
  •  go-up   go-down


44. Qian HL, Peng XX, Chen SH, Ye HM, Qiu JH: p62 Expression in primary carcinomas of the digestive system. World J Gastroenterol; 2005 Mar 28;11(12):1788-92
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] p62 Expression in primary carcinomas of the digestive system.
  • AIM: To characterize p62 expression and define the relationship between p62 expression and cell proliferation in primary carcinomas of the digestive system.
  • METHODS: p62 expression was characterized in surgically resected tumor specimens from 60 patients with primary carcinomas of the digestive tract (including 22 esophageal carcinomas, 17 gastric carcinomas, and 21 colorectal carcinomas) and 40 patients with hepatocellular carcinoma (HCC) by immunohistochemistry (IHC).
  • The cell proliferation was determined by IHC of Ki-67 in 40 patients with HCC.
  • RESULTS: Twenty-two cases of esophageal carcinoma were histopathologically diagnosed as squamous cell carcinoma.
  • p62 expression in primary carcinomas of the gastrointestinal tract (60/60,100%) was higher than that (27/40, 67.5%) of HCC (P<0.01, chi(2) = 19.63).
  • CONCLUSION: p62 expression is common in carcinomas of the digestive system and higher in carcinomas of the gastrointestinal tract than in primary HCC. p62 is a cellular differentiation-related protein.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Digestive System Neoplasms / metabolism. Liver Neoplasms / metabolism. RNA-Binding Proteins / metabolism
  • [MeSH-minor] Adenocarcinoma / metabolism. Adenocarcinoma / pathology. Adenocarcinoma, Mucinous / metabolism. Adenocarcinoma, Mucinous / pathology. Adult. Aged. Cell Division. Colorectal Neoplasms / metabolism. Colorectal Neoplasms / pathology. Esophageal Neoplasms / metabolism. Esophageal Neoplasms / pathology. Humans. Immunohistochemistry. Middle Aged. Stomach Neoplasms / metabolism. Stomach Neoplasms / pathology

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15793865.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / P62 protein, human; 0 / RNA-Binding Proteins
  • [Other-IDs] NLM/ PMC4305875
  •  go-up   go-down


45. Pineau P, Tiollais P: [Hepatitis B vaccination: a major player in the control of primary liver cancer]. Pathol Biol (Paris); 2010 Dec;58(6):444-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Hepatitis B vaccination: a major player in the control of primary liver cancer].
  • In worst cases, chronic hepatitis B ultimately leads to primary liver cancer.
  • Populations the more at risk to develop hepatocellular carcinoma (HCC), i.e. patients infected perinatally, reside essentially in Asia.
  • Finally, lack of early immunization of newborns in developing countries still represents a major limitation to the progresses against liver cancer.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis B Vaccines. Liver Neoplasms / prevention & control. Vaccination
  • [MeSH-minor] Adult. Africa / epidemiology. Asia / epidemiology. Carrier State. Child. Developing Countries. Disease Progression. Endemic Diseases. Female. Hepatitis B virus / immunology. Hepatitis B virus / pathogenicity. Hepatitis B, Chronic / complications. Hepatitis B, Chronic / epidemiology. Hepatitis C, Chronic / epidemiology. Humans. Immunization Schedule. Incidence. Infant, Newborn. Infectious Disease Transmission, Vertical / prevention & control. Male. Pregnancy. Pregnancy Complications, Infectious / virology

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Immunization.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 19896296.001).
  • [ISSN] 1768-3114
  • [Journal-full-title] Pathologie-biologie
  • [ISO-abbreviation] Pathol. Biol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Chemical-registry-number] 0 / Hepatitis B Vaccines
  •  go-up   go-down


46. Chhabra DG, Shah RC, Parikh V, Jagannath P: Radiofrequency ablation of liver tumors: experience with open and percutaneous approach. Indian J Gastroenterol; 2006 Mar-Apr;25(2):66-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiofrequency ablation of liver tumors: experience with open and percutaneous approach.
  • BACKGROUND: Radiofrequency ablation (RFA), a thermal coagulation technique, has been used for ablation of primary and secondary liver tumors.
  • METHODS: Over a 24-month period, 41 patients, including 20 with hepatocellular cancer (HCC), 14 with liver metastases from colorectal tumors and 7 with metastases from other tumors, underwent RFA in our institution.
  • All patients with liver metastases had successful tumor ablation.
  • CONCLUSIONS: RFA is a safe and promising technique for the treatment of non-resectable HCC and liver metastases, in the short term.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Postoperative Complications

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16763333.001).
  • [ISSN] 0254-8860
  • [Journal-full-title] Indian journal of gastroenterology : official journal of the Indian Society of Gastroenterology
  • [ISO-abbreviation] Indian J Gastroenterol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  •  go-up   go-down


47. Qian S, Shi M, Zhang H, Zhang B, Xu DP, Wang FS: [Phenotype and function of myeloid dendritic cells pulsed with hepatitis B virus antigens in patients with HBV-associated hepatocellular carcinoma]. Zhonghua Yi Xue Za Zhi; 2005 Jan 26;85(4):248-52
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Phenotype and function of myeloid dendritic cells pulsed with hepatitis B virus antigens in patients with HBV-associated hepatocellular carcinoma].
  • OBJECTIVE: To investigate the characteristics of phenotype and function of myeloid dendritic cells (mDCs) pulsed with HBV antigens derived from HBV-associated hepatocellular carcinoma (HCC) patients.
  • METHODS: Peripheral blood mononuclear cells (PBMCs) were collected, using blood cell separator, from 21 primary HCC patients and 4 healthy donors. mDCs were propagated in serum-free AIM-V medium in the presence of cytokine cocktail, and pulsed with HBcAg or HBsAg.
  • Autologous T cells proliferation stimulated by mDC was tested by non-radioactive cell proliferation assay kit.
  • T cell proliferation assay revealed an impaired allostimulatory capacity of mDCs in HCC and the stimulatory capacity of the mDCs pulsed with HBcAg to induce proliferation of autologous T cells was more powerful than that pulsed with HBsAg (P < 0.05).
  • [MeSH-major] Carcinoma, Hepatocellular / immunology. Dendritic Cells / immunology. Hepatitis B Antigens / immunology. Hepatitis B, Chronic / immunology. Liver Neoplasms / immunology
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunophenotyping. Male. Middle Aged

  • Genetic Alliance. consumer health - Hepatitis.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15854486.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Hepatitis B Antigens
  •  go-up   go-down


48. Park WS, Cho YG, Kim CJ, Song JH, Lee YS, Kim SY, Nam SW, Lee SH, Yoo NJ, Lee JY: Hypermethylation of the RUNX3 gene in hepatocellular carcinoma. Exp Mol Med; 2005 Aug 31;37(4):276-81
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hypermethylation of the RUNX3 gene in hepatocellular carcinoma.
  • To elucidate the potential etiological role of the RUNX3 gene in the development of hepatocellular carcinoma (HCC), we have analyzed the methylation status of 5' CpG island of the RUNX3 gene in a series of 73 HCC tissues and 11 liver cell lines.
  • Expectedly, promoter methylation of RUNX3 gene was found in 2 (2.7%) of 73 corresponding normal liver, whereas 30 (41.1%) of 73 HCCs and 4 (40%) of 10 liver cancer cell lines showed hypermethylation of the gene, respectively.
  • There was no significant difference between promoter hypermethylaion and clinicopathologic parameters of primary HCC samples, including histologic grade, microvascular invasion, and clinical stage.
  • Interestingly, demethylating agent 5-aza-2-deoxycytidine induced reactivation and more potent expression of RUNX3 gene in HCC cell lines.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. DNA Methylation. DNA, Neoplasm / metabolism. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Azacitidine / analogs & derivatives. Azacitidine / pharmacology. Female. Humans. Male. Middle Aged. Promoter Regions, Genetic

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. AZACITIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16155404.001).
  • [ISSN] 1226-3613
  • [Journal-full-title] Experimental & molecular medicine
  • [ISO-abbreviation] Exp. Mol. Med.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Korea (South)
  • [Chemical-registry-number] 0 / DNA, Neoplasm; 776B62CQ27 / decitabine; M801H13NRU / Azacitidine
  •  go-up   go-down


49. Abdel Wahab M, Lawal AR, EL Hanafy E, Salah T, Hamdy E, Sultan AM: Caudate lobe resection: an Egyptian center experience. Langenbecks Arch Surg; 2009 Nov;394(6):1057-63
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Indications for hepatectomy in patients with ICLR include hepatocellular carcinoma, primary hepatic carcinoid tumor, cavernous hemangioma, and adenoma.
  • [MeSH-major] Adenoma / surgery. Carcinoid Tumor / surgery. Carcinoma, Hepatocellular / surgery. Hemangioma, Cavernous / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Cohort Studies. Egypt. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Carcinoid Tumors.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 1999 Jan;23(1):97-101 [9841771.001]
  • [Cites] Hepatogastroenterology. 2001 May-Jun;48(39):808-11 [11462929.001]
  • [Cites] J Gastrointest Surg. 2008 Jul;12(7):1288-92 [18040745.001]
  • [Cites] Surgery. 2002 Oct;132(4):697-708; discussion 708-9 [12407355.001]
  • [Cites] Surg Gynecol Obstet. 1992 Jul;175(1):17-24 [1621195.001]
  • [Cites] World J Surg. 1996 Jun;20(5):562-5; discussion 565-6 [8661631.001]
  • [Cites] Am J Surg. 2005 Sep;190(3):451-5 [16105535.001]
  • [Cites] Surg Gynecol Obstet. 1990 Aug;171(2):160-2 [2382196.001]
  • [Cites] World J Gastroenterol. 2003 Oct;9(10):2169-73 [14562371.001]
  • [Cites] Br J Surg. 1996 Aug;83(8):1076-81 [8869306.001]
  • [Cites] HPB Surg. 1998;11(2):87-93; discussion 93-5 [9893238.001]
  • [Cites] Surgery. 1980 May;87(5):593-5 [7368110.001]
  • [Cites] J Am Coll Surg. 2005 Mar;200(3):345-52 [15737844.001]
  • [Cites] Ann Surg. 2001 Jan;233(1):45-50 [11141224.001]
  • [Cites] Am J Surg. 2008 Aug;196(2):245-51 [18571618.001]
  • [Cites] Hepatology. 1994 Apr;19(4):911-5 [8138265.001]
  • [Cites] Hepatogastroenterology. 2008 May-Jun;55(84):831-5 [18705277.001]
  • [Cites] World J Surg. 1990 Jul-Aug;14(4):535-43; discussion 544 [2166381.001]
  • (PMID = 19763602.001).
  • [ISSN] 1435-2451
  • [Journal-full-title] Langenbeck's archives of surgery
  • [ISO-abbreviation] Langenbecks Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


50. Li SP, Peng QQ, Ding T, Xu J, Zhang CQ, Feng KT, Li JQ: [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):523-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical significance of regulatory T cells proportion in the peripheral blood and tumor tissue in primary hepatocellular carcinoma].
  • OBJECTIVE: To investigate the clinical significance of the amount of regulatory T cells (Treg) in the peripheral blood CD4+ cells and tumor tissue in primary hepatocellular carcinoma (HCC).
  • The mean number of Treg in tumor tissue was (15.69 +/- 13.29)/mm2, but none or very few Treg was detected in the normal liver tissue, para-cancerous liver tissue, and HBV-infected liver tissue.
  • CONCLUSION: Regulatory T cells in the circulatory blood and tumor tissue are increased in patients with hepatocellular carcinoma.
  • Detection of regulatory T cells both in the preoperative peripheral blood CD4+ cells and tumor tissue may be used as a potential immunological prognostic indicator for the hepatocellular carcinoma patients after radical resection.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. T-Lymphocytes, Regulatory / pathology
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Follow-Up Studies. Forkhead Transcription Factors / metabolism. Hepatectomy. Hepatitis B / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Recurrence, Local. Proportional Hazards Models. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062720.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


51. Zhang F, Chen XP, Zhang W, Dong HH, Xiang S, Zhang WG, Zhang BX: Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence. Histopathology; 2008 Jan;52(2):224-32
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular cholangiocarcinoma originating from hepatic progenitor cells: immunohistochemical and double-fluorescence immunostaining evidence.
  • AIMS: Combined hepatocellular cholangiocarcinoma (CHC) is a rare form of primary liver cancer, showing a mixture of hepatocellular and biliary features.
  • METHODS AND RESULTS: Twelve cases of CHC were studied by immunohistochemistry for hepatocytic (hepPar1, alpha-fetoprotein), cholangiocytic cytokeratin [(CK) 7, CK19], hepatic progenitor cell (OV-6), haematopoietic stem cell (c-kit, CD34), as well as CD45 and chromogranin-A markers.
  • [MeSH-major] Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Hepatocytes / pathology. Liver Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] Adult. Aged. Cell Transformation, Neoplastic / metabolism. Cell Transformation, Neoplastic / pathology. Female. Humans. Keratin-19 / metabolism. Keratin-7 / metabolism. Male. Middle Aged. Proto-Oncogene Proteins c-kit / metabolism. Receptor, PAR-1 / metabolism


52. Asechi H, Hatano E, Nitta T, Tada M, Iwaisako K, Tamaki N, Nagata H, Narita M, Yanagida A, Ikai I, Uemoto S: Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line. Int J Oncol; 2010 Jul;37(1):89-96
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Resistance to cisplatin-induced apoptosis via PI3K-dependent survivin expression in a rat hepatoma cell line.
  • Hepatocellular carcinoma (HCC) is known to be resistant to chemotherapy.
  • Survivin, a member of the inhibitor of apoptosis proteins, is overexpressed in most cancers but is absent in most normal adult tissue.
  • We confirmed induction of survivin expression in hepatoma in the N-diethylnitrosamine (DEN) induced rat and in the rat hepatoma cell line (K-251).
  • We examined cell proliferation after treatment with cisplatin (CDDP) in the presence and absence of siRNA or the phosphatidylinositol 3-kinase (PI3K) inhibitor LY294002 to suppress survivin or PI3K/Akt, respectively.
  • Expression of survivin was observed primary in the nuclei and in the cytoplasm with immunohistochemistry.
  • Expression of survivin was also observed primarily in the nuclei and in the cytoplasm of the K-251 rat hepatoma cell line.
  • Our results indicate that survivin expression via PI3K contributes to resistance to CDDP-induced apoptosis in a rat hepatoma cell line.
  • [MeSH-major] Apoptosis / drug effects. Carcinoma, Hepatocellular / genetics. Cisplatin / pharmacology. Drug Resistance, Neoplasm / genetics. Liver Neoplasms, Experimental / genetics. Microtubule-Associated Proteins / genetics. Phosphatidylinositol 3-Kinases / physiology
  • [MeSH-minor] Animals. Antineoplastic Agents / pharmacology. Cell Line, Tumor. Cells, Cultured. Diethylnitrosamine. Gene Expression Regulation, Neoplastic / drug effects. Male. RNA, Small Interfering / pharmacology. Rats. Rats, Sprague-Dawley

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. N-NITROSODIETHYLAMINE .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20514400.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Birc5 protein, rat; 0 / Microtubule-Associated Proteins; 0 / RNA, Small Interfering; 3IQ78TTX1A / Diethylnitrosamine; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


53. Liang SN, Liu LL, Su HY, Feng B, Zhao GS, Xu K: [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma]. Zhonghua Zhong Liu Za Zhi; 2008 Oct;30(10):790-2
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Analysis of severe complications after transcatheter arterial chemoembolization for primary hepatocellular carcinoma].
  • OBJECTIVE: To investigate the cause and treatment as well as prevention measures of rarely occurring severe complications after transcatheter arterial chemoembolization (TACE) for primary hepatic carcinoma.
  • METHODS: 573 consecutive patients with primary hepatic carcinoma underwent a total of 1252 TACE procedures from January 2005 to July 2007.
  • CONCLUSION: The rarely occurring severe complications after transcatheter arterial chemoembolization for primary hepatic carcinoma is correlated with poor hepatic function and portal hypertension before therapy, overdose and reflux of chemotherapeutic agents or allotopic chemoembolism, etc.
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Gastrointestinal Hemorrhage / etiology. Liver Failure / etiology. Liver Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / adverse effects. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Epirubicin / administration & dosage. Epirubicin / adverse effects. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Hepatic Encephalopathy / etiology. Humans. Iodized Oil / administration & dosage. Iodized Oil / adverse effects. Male. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Pulmonary Embolism / etiology. Young Adult

  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19173817.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin; 8001-40-9 / Iodized Oil; U3P01618RT / Fluorouracil
  •  go-up   go-down


54. Fernandes ML, Lin CC, Lin CJ, Chen WT, Lin SM: Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation. Br J Surg; 2009 Jul;96(7):756-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk of tumour progression in early-stage hepatocellular carcinoma after radiofrequency ablation.
  • BACKGROUND: This study aimed objectively to quantify the risk of tumour progression beyond the Milan criteria following radiofrequency (RF) ablation for hepatocellular carcinoma (HCC) and to identify factors associated with tumour progression.
  • METHODS: Some 111 patients (136 tumours) with liver cirrhosis undergoing RF ablation for HCC within Milan criteria between February 2004 and June 2007 were enrolled in the study.
  • On multivariable analysis, factors independently associated with tumour progression were failure to achieve primary technique effectiveness (P = 0.005), alpha-fetoprotein level above 200 ng/ml (P = 0.013) and Child-Pugh grade B cirrhosis (P = 0.034).
  • Failure to achieve primary RF ablation technique effectiveness was associated with tumour location in segment VIII (P = 0.033), a cool-down temperature of 70 degrees C or less (P = 0.043) and multiple overlapping ablations (P = 0.029).
  • Primary technique failure is identified as a risk factor for tumour progression.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Catheter Ablation / methods. Neoplasm Recurrence, Local / pathology
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Disease Progression. Epidemiologic Methods. Female. Humans. Male. Middle Aged. Risk Factors. Severity of Illness Index. Treatment Outcome. alpha-Fetoproteins / metabolism

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 British Journal of Surgery Society Ltd.
  • (PMID = 19526609.001).
  • [ISSN] 1365-2168
  • [Journal-full-title] The British journal of surgery
  • [ISO-abbreviation] Br J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / alpha-Fetoproteins
  •  go-up   go-down


55. Szumera M, Czauderna P, Popadiuk S, Renke J, Sznurkowska K, Gołebiewski J, Korzon M: [Pulmonary metastases in children with solid tumours--own experiences]. Med Wieku Rozwoj; 2006 Jul-Sep;10(3 Pt 1):665-75
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The most often lung metastases were recognised in osteosarcoma (15-57.8%) and carcinoma embryonale (3-11.6%).
  • The statistically significant difference was found in comparison of complete surgery versus incomplete (p=0.02), no significance was found in primary or secondary metastases (p=0.27).
  • [MeSH-minor] Adolescent. Adult. Bone Neoplasms / pathology. Bone Neoplasms / surgery. Carcinoma, Embryonal / secondary. Carcinoma, Embryonal / surgery. Carcinoma, Hepatocellular / secondary. Carcinoma, Hepatocellular / surgery. Child. Endocrine Gland Neoplasms / pathology. Endocrine Gland Neoplasms / surgery. Female. Follow-Up Studies. Humans. Liver Neoplasms / pathology. Liver Neoplasms / surgery. Male. Neuroblastoma / secondary. Neuroblastoma / surgery. Oncology Service, Hospital / statistics & numerical data. Osteosarcoma / secondary. Osteosarcoma / surgery. Poland. Prognosis. Retrospective Studies. Sarcoma, Ewing / secondary. Sarcoma, Ewing / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17317898.001).
  • [Journal-full-title] Medycyna wieku rozwojowego
  • [ISO-abbreviation] Med Wieku Rozwoj
  • [Language] pol
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Poland
  •  go-up   go-down


56. Kassahun WT, Fangmann J, Harms J, Hauss J, Bartels M: Liver resection and transplantation in the management of hepatocellular carcinoma: a review. Exp Clin Transplant; 2006 Dec;4(2):549-58
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver resection and transplantation in the management of hepatocellular carcinoma: a review.
  • Hepatocellular carcinoma (HCC) accounts for more than 80% of all primary liver cancers and is one of the most common malignancies worldwide.
  • Effective treatment for HCC includes liver resection and liver transplantation.
  • Partial hepatectomy is the therapy of choice in patients with HCC and a noncirrhotic liver.
  • Usually, liver transplantation is not indicated for such patients, although in individual cases, transplantation may be considered.
  • For most cirrhotic patients who fulfill the Milan criteria, liver transplantation is the ultimate treatment option.
  • Liver transplantation restores liver function and ensures the removal of all hepatic foci of tumor as well as tissue with a high oncogenic potential for early tumor recurrence.
  • Because of the present lack of available organs, living-donor liver transplantation (LDLT) is an increasingly popular alternative.
  • Strategies to reduce tumor growth in patients who are awaiting liver transplantation are important to ensure that those individuals continue to fulfill the Milan criteria for transplantation.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy / methods. Liver Neoplasms / surgery. Liver Transplantation / physiology. Tissue Donors. Tissue and Organ Harvesting / methods
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17238857.001).
  • [ISSN] 1304-0855
  • [Journal-full-title] Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation
  • [ISO-abbreviation] Exp Clin Transplant
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Turkey
  • [Number-of-references] 99
  •  go-up   go-down


57. Zhang K, Kokudo N, Hasegawa K, Arita J, Tang W, Aoki T, Imamura H, Sano K, Sugawara Y, Makuuchi M: Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma. Arch Surg; 2007 Dec;142(12):1170-5; discussion 1176
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of new tumors by intraoperative ultrasonography during repeated hepatic resections for hepatocellular carcinoma.
  • OBJECTIVE: To evaluate the efficacy of intraoperative (IO) ultrasonography (US) as compared with other imaging modalities on the primary and repeated hepatectomies for hepatocellular carcinoma.
  • PATIENTS: From January 6, 1995, to December 26, 2002, 430 patients underwent 555 operations for hepatocellular carcinoma.
  • MAIN OUTCOME MEASURES: New tumors detected by IOUS at the primary and second hepatectomies were analyzed.
  • Intraoperative US detected 56 new tumors in 30 cases (7.0%) at the primary hepatectomy and 13 new tumors in 8 cases (7.3%) at the second hepatectomy.
  • The mean +/- SD tumor sizes were 8.7 +/- 3.8 mm and 9.0 +/- 5.2 mm at the primary and second resections, respectively.
  • The preoperative surgical plan was changed owing to the IOUS findings alone in 24 cases (5.6%) at the primary hepatectomy and in 7 cases (6.4%) at the second.
  • Although recurrence was frequent in patients with new tumors at the primary hepatectomy, long-term survival after appropriate treatment for recurrence was similar to that of patients without new tumors.
  • [MeSH-major] Carcinoma, Hepatocellular / ultrasonography. Hepatectomy. Liver Neoplasms / ultrasonography. Neoplasm Recurrence, Local / ultrasonography
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Humans. Intraoperative Period. Male. Middle Aged. Reoperation. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18086983.001).
  • [ISSN] 1538-3644
  • [Journal-full-title] Archives of surgery (Chicago, Ill. : 1960)
  • [ISO-abbreviation] Arch Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


58. Lin G, Toh CH, Wu RC, Ko SF, Ng SH, Chou WC, Tseng JH: Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging. Int J Clin Pract; 2008 Aug;62(8):1199-205
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined hepatocellular cholangiocarcinoma: prognostic factors investigated by computed tomography/magnetic resonance imaging.
  • This study was designed to assess the clinical usefulness of imaging for predicting the prognosis of patients with combined hepatocellular cholangiocarcinoma (cHCC-CC).
  • Analysing the survival of our patients by using clinical stages of the newly updated American Joint Committee on Cancer (AJCC) classification for liver neoplasm based on the imaging findings, we found significant differences between stages I/II and III (p < 0.001) and between stages III and IV (p = 0.040).
  • [MeSH-major] Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic / pathology. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / pathology. Liver Neoplasms / pathology. Magnetic Resonance Imaging / standards. Neoplasms, Multiple Primary / pathology. Tomography, X-Ray Computed / standards
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neoplasm Invasiveness. Neoplasm Staging. Prognosis. Survival Analysis. Survival Rate

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - MRI Scans.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17537192.001).
  • [ISSN] 1742-1241
  • [Journal-full-title] International journal of clinical practice
  • [ISO-abbreviation] Int. J. Clin. Pract.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] England
  •  go-up   go-down


59. Bharat A, Brown DB, Crippin JS, Gould JE, Lowell JA, Shenoy S, Desai NM, Chapman WC: Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival. J Am Coll Surg; 2006 Oct;203(4):411-20
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-liver transplantation locoregional adjuvant therapy for hepatocellular carcinoma as a strategy to improve longterm survival.
  • BACKGROUND: Preorthotopic liver transplantation locoregional therapy (LRT) for hepatocellular carcinoma (HCC) reduces drop-out rates in patients awaiting orthotopic liver transplantation (OLT).
  • CONCLUSIONS: OLT is a viable treatment option for primary HCC.
  • LRT substantially downstages the primary tumor and improves longterm survival in patients with advanced disease.
  • [MeSH-major] Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / therapy. Liver Neoplasms / mortality. Liver Neoplasms / therapy. Liver Transplantation. Neoadjuvant Therapy
  • [MeSH-minor] Adult. Aged. Catheter Ablation. Chemoembolization, Therapeutic. Cohort Studies. Ethanol / administration & dosage. Female. Humans. Male. Middle Aged. Retrospective Studies. Solvents / administration & dosage. Survival Rate. Treatment Outcome

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. ETHANOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17000383.001).
  • [ISSN] 1072-7515
  • [Journal-full-title] Journal of the American College of Surgeons
  • [ISO-abbreviation] J. Am. Coll. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Solvents; 3K9958V90M / Ethanol
  •  go-up   go-down


60. Murakami T, Ishimaru H, Sakamoto I, Uetani M, Matsuoka Y, Daikoku M, Honda S, Koshiishi T, Fujimoto T: Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence. Cardiovasc Intervent Radiol; 2007 Jul-Aug;30(4):696-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation and transcatheter arterial chemoembolization for hypervascular hepatocellular carcinoma: rate and risk factors for local recurrence.
  • PURPOSE: To analyze local recurrence-free rates and risk factors for recurrence following percutaneous radiofrequency ablation (RFA) or transcatheter arterial chemoembolization (TACE) for hypervascular hepatocellular carcinoma (HCC).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / surgery. Chemoembolization, Therapeutic / methods. Electrocoagulation / methods. Liver Neoplasms / drug therapy. Liver Neoplasms / surgery. Neoplasm Recurrence, Local / etiology. Neoplasms, Multiple Primary / drug therapy. Neoplasms, Multiple Primary / radiotherapy. Neovascularization, Pathologic / drug therapy. Neovascularization, Pathologic / surgery
  • [MeSH-minor] Adult. Aged. Angiography. Disease-Free Survival. Epirubicin / administration & dosage. Follow-Up Studies. Humans. Male. Middle Aged. Mitomycin / administration & dosage. Retrospective Studies. Risk Factors. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. MITOMYCIN C .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17497071.001).
  • [ISSN] 0174-1551
  • [Journal-full-title] Cardiovascular and interventional radiology
  • [ISO-abbreviation] Cardiovasc Intervent Radiol
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 3Z8479ZZ5X / Epirubicin; 50SG953SK6 / Mitomycin
  •  go-up   go-down


61. Kinoshita Y, Tajiri T, Souzaki R, Tatsuta K, Higashi M, Izaki T, Takahashi Y, Taguchi T: Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study. J Pediatr Hematol Oncol; 2008 Jun;30(6):447-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diagnostic value of lectin reactive alpha-fetoprotein for neoinfantile hepatic tumors and malignant germ cell tumors: preliminary study.
  • BACKGROUND AND PURPOSE: The serum alpha-fetoprotein (AFP) level has been used as a tumor marker for hepatoblastoma, and malignant germ cell tumors in pediatric patients.
  • The AFP has 3 isoforms (L1, L2, L3), and the usefulness of the L3 fraction as a diagnostic marker for the adult hepatocellular carcinoma is well known.
  • MATERIALS AND METHODS: From 2003 to 2006, two cases of hepatoblastoma, and 5 cases of germ cell tumor, all of which were neoinfantile, were treated in our department.
  • DISCUSSION: Our results indicated that the level of the L3 fraction accurately confirmed the existence, or the malignant potential of hepatic tumor or germ cell tumor.
  • [MeSH-major] Biomarkers, Tumor / blood. Hepatoblastoma / blood. Liver Neoplasms / blood. Neoplasms, Germ Cell and Embryonal / blood. alpha-Fetoproteins / analysis


62. Chen GH, Fu BS, Cai CJ, Lu MQ, Yang Y, Yi SH, Xu C, Li H, Wang GS, Zhang T: A single-center experience of retransplantation for liver transplant recipients with a failing graft. Transplant Proc; 2008 Jun;40(5):1485-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A single-center experience of retransplantation for liver transplant recipients with a failing graft.
  • With the accumulation of orthotopic liver transplantation (OLT) recipients, an increased number of patients with graft failure need retransplantation (re-OLT).
  • This study was undertaken to examine our clinical experience of re-OLT for patients with poor graft function after primary transplantation at a single center.
  • The indications included bile leak (2 cases), biliary stricture (16 cases), recurrence of hepatocellular carcinoma (HCC) (5 cases), hepatic artery stenosis (4 cases), hepatic artery thrombosis (HAT) (2 cases), and hepatitis B recurrence (3 cases).
  • All patients underwent modified piggyback liver transplantations with cadaveric allografts.
  • Re-OLT is the only therapeutic option for a failing liver graft.
  • [MeSH-major] Liver Transplantation / adverse effects. Reoperation / statistics & numerical data
  • [MeSH-minor] Adult. Aged. Cause of Death. Female. Humans. Male. Middle Aged. Postoperative Complications / classification. Postoperative Complications / surgery. Retrospective Studies. Transplantation, Homologous. Treatment Failure

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18589134.001).
  • [ISSN] 0041-1345
  • [Journal-full-title] Transplantation proceedings
  • [ISO-abbreviation] Transplant. Proc.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


63. Wu D, Bao WG, Ding YH: [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2005 Dec;25(12):1066-9
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical and experimental study of xiaoshui decoction in the treatment of primary liver cancer caused ascites].
  • OBJECTIVE: To observe the clinical efficacy of Xiaoshui Decoction (XSD) in treating ascites in patients suffered from primary liver cancer of Pi-deficiency with damp harassment syndrome (PDDHS) as well as to study the effect through the experiment in mice.
  • METHODS: Sixty-one patients confirmed to be primary liver cancer of PDDHS and accompanied with ascites were randomly divided into the treated group (n=33) and the control group (n=28).
  • Experimental study showed that on the two mice models of ascites induced by inoculating two kinds of tumor cell, the effect of XSD was superior to that of the control group in aspects of reducing ascites and prolonging survival period, showing significant difference (P < 0.05).
  • CONCLUSION: Satisfactory short-term efficacy in treating primary liver cancer with ascites of the Pi-deficiency with damp harassment syndrome could be obtained by XSD.
  • XSD can also improve the symptoms and QOL of patients, therefore, it is an effective and reliable remedy for treatment of primary liver cancer with ascites.


64. Torisu Y, Watanabe A, Nonaka A, Midorikawa Y, Makuuchi M, Shimamura T, Sugimura H, Niida A, Akiyama T, Iwanari H, Kodama T, Zeniya M, Aburatani H: Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF. Cancer Sci; 2008 Jun;99(6):1139-46
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Human homolog of NOTUM, overexpressed in hepatocellular carcinoma, is regulated transcriptionally by beta-catenin/TCF.
  • In comparative analysis of the gene expression profiles in primary human hepatocellular carcinomas (HCC) and normal organs, we observed that the human ortholog of Drosophila Notum was overexpressed markedly in a subset of HCC, but expressed rarely in adult normal tissues.
  • Immunoblotting confirmed the overexpression of NOTUM protein in 12 of 40 primary HCC cases (30%).
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Drosophila Proteins / genetics. Gene Expression Regulation, Neoplastic. Liver Neoplasms / genetics. Transcription, Genetic. beta Catenin / metabolism
  • [MeSH-minor] Adult. Aged. Animals. Antibodies, Monoclonal. Chromatin Immunoprecipitation. Female. Gene Expression Profiling. Humans. Immunization. Immunoblotting. Male. Mice. Middle Aged. Mutagenesis, Site-Directed. Oligonucleotide Array Sequence Analysis. Promoter Regions, Genetic. Rabbits. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / immunology. Recombinant Fusion Proteins / metabolism. Signal Transduction. TCF Transcription Factors / genetics. TCF Transcription Factors / metabolism. Transcription Factor 7-Like 2 Protein. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18429952.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / CTNNB1 protein, human; 0 / Drosophila Proteins; 0 / Notum protein, Drosophila; 0 / Recombinant Fusion Proteins; 0 / TCF Transcription Factors; 0 / TCF7L2 protein, human; 0 / Tcf7l2 protein, mouse; 0 / Transcription Factor 7-Like 2 Protein; 0 / beta Catenin
  •  go-up   go-down


65. Sornmayura P, Boonsakan P, Sobhonslidsuk A, Sriphojanart S, Euanorasetr C, Bunyaratvej S: Dysplastic nodules and small primary carcinoma of the liver: a study detecting the early morphological changes during hepatocarcinogenesis. J Med Assoc Thai; 2007 Feb;90(2):352-62
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dysplastic nodules and small primary carcinoma of the liver: a study detecting the early morphological changes during hepatocarcinogenesis.
  • OBJECTIVE: Detect the early histological changes relating to human hepatocarcinogenesis in three nodular hepatocellular lesions.
  • MATERIAL AND METHOD: Three cases of dysplastic nodules and one of small hepatocellular carcinoma were obtained from the authors' surgical-pathology file during 2000-2005 for a histopathological study in relevance to the early changes during hepatocarcinogenesis by employing hematoxylin and eosin stain, as well as some immunohistochemical staining.
  • RESULTS: One nodular hepatocellular lesion, diagnosed as a complex lesion of focal nodular hyperplasia contained a microscopic focus (1.5 mm in diameter) of combined hepatocellular and cholangiocarcinoma.
  • CONCLUSION: The small dysplastic hepatocytes subjected to neoplastic transformation combined hepatocellular and cholangiocarcinoma and are the precursorial cells of hepatocellular carcinoma.
  • Chronic viral hepatitis B or C, aflatoxin B, and nitrosamine(s), as well as some nodular hepatocellular lesions share distinct roles in the complex process of hepatocarcinogenesis pertaining to this Southeast Asian country.
  • [MeSH-major] Hepatocytes / pathology. Liver Neoplasms / diagnosis
  • [MeSH-minor] Adult. Early Diagnosis. Female. Humans. Male. Middle Aged. Retrospective Studies. Time Factors

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17375643.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Thailand
  •  go-up   go-down


66. Sapisochin G, Bilbao I, Balsells J, Dopazo C, Caralt M, Lázaro JL, Castells L, Allende H, Charco R: Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series. World J Surg; 2010 Sep;34(9):2146-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optimization of liver transplantation as a treatment of intrahepatic hepatocellular carcinoma recurrence after partial liver resection: experience of a single European series.
  • BACKGROUND: The aim of this study was to ascertain the outcome of liver transplantation (LT) due to hepatocellular carcinoma (HCC) in patients who had undergone previous liver resection (LR) for HCC.
  • METHODS: A case-control study (1:2) was designed to compare patients who underwent LT due to HCC recurrence with a previous LR for HCC (study group) with those who underwent LT for primary HCC but without previous LR (control group).
  • RESULTS: From January 1990 to December 2007, a total of 303 cirrhotic patients with primary HCC were evaluated for surgery.
  • Primary LT was performed in 191 and LR in 100.
  • CONCLUSIONS: Liver transplantation can be safely performed after a previous LR for HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation. Neoplasm Recurrence, Local / surgery
  • [MeSH-minor] Adult. Aged. Disease-Free Survival. Female. Humans. Liver Cirrhosis / complications. Liver Function Tests. Male. Middle Aged. Prognosis. Reoperation. Treatment Outcome. Ultrasonography


67. Ikeda S: [Adult-onset citrullinemia]. Brain Nerve; 2007 Jan;59(1):59-66
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Adult-onset citrullinemia].
  • Adult-onset citrullinemia (CTLN2) is a rare hereditary metabolic disorder characterized by highly increased concentration of citrulline and ammonia in the plasma, which is ascribed to a deficiency of argininosuccinate synthetase (ASS), one of the urea cycle enzymes mainly located in the liver.
  • However, in 1995 the first CTLN2 patient who was successfully treated by living-related liver transplantation was reported and since then more than 30 patients had underwent this operation in our country, showing good outcomes.
  • No primary defect had not been found within ASS gene locus, but the causative gene of this disorder is now identified as the "citrin gene", which might act as a aspartate/glutamate transporter in mitochondria.
  • Different phenotypes are seen in the individuals with a citrin deficiency: neonatal intrahepatic cholestasis, juvenile-onset chronic pancreatitis and hepatocellular carcinoma without cirrhosis can precede the appearance of CTLN2.
  • [MeSH-minor] Administration, Oral. Adult. Age of Onset. Arginine / administration & dosage. Argininosuccinate Synthase. Calcium-Binding Proteins / genetics. Cholestasis, Intrahepatic / etiology. Chronic Disease. Glycerol / contraindications. Humans. Liver Neoplasms / etiology. Liver Transplantation. Mutation. Organic Anion Transporters / genetics. Pancreatitis / etiology. Phenotype

  • Genetic Alliance. consumer health - Citrullinemia.
  • Hazardous Substances Data Bank. GLYCERIN .
  • Hazardous Substances Data Bank. (L)-ARGININE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17354380.001).
  • [ISSN] 1881-6096
  • [Journal-full-title] Brain and nerve = Shinkei kenkyū no shinpo
  • [ISO-abbreviation] Brain Nerve
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Calcium-Binding Proteins; 0 / Organic Anion Transporters; 1340-08-5 / citrin; 94ZLA3W45F / Arginine; EC 6.3.4.5 / Argininosuccinate Synthase; PDC6A3C0OX / Glycerol
  • [Number-of-references] 34
  •  go-up   go-down


68. Zhang ZM, Wang G, Chen C, Yang ZX, Jin F, San JL, Xu W, Li Q, Li ZP, Wang D: Rapid induction of PC3/BTG2 gene by hepatopoietin or partial hepatectomy and its mRNA expression in hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int; 2009 Jun;8(3):288-93
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rapid induction of PC3/BTG2 gene by hepatopoietin or partial hepatectomy and its mRNA expression in hepatocellular carcinoma.
  • BACKGROUND: The anti-proliferative gene, PC3 (pheoch-romocytoma cell 3)/BTG2 (B-cell translocation gene 2), is one of the early growth response genes and belongs to the BTG/Tob protein family.
  • This study aimed to assess the effects of recombinant human hepatopoietin (HPO) and partial hepatectomy on rapidly induced expression of immediate-early genes and to investigate the expression of PC3/BTG2 mRNA in hepatocellular carcinoma (HCC) at different stages of progression.
  • METHODS: After a rat model of partial hepatectomy was established, we investigated gene expression within 1 hour after 2/3 partial hepatectomy by representational difference analysis and in a primary cultured hepatocyte system.
  • The expression levels of PC3/BTG2 from liver tissues of the rat model were assessed by RT-PCR and Northern blotting.
  • HPO rapidly induced the expression of the genes c-fos, LRF-1, and PC3 in primary cultured rat hepatocytes, which might be one of the molecular mechanisms by which HPO stimulates hepatocyte proliferation.
  • Positive BTG2 mRNA expression was detected in 71.19% (42/59) of the HCC samples and in 75% (3/4) of the normal liver tissue samples obtained from the region around the HCC tissues.
  • PC3/BTG2 mRNA is highly expressed in HCC cells and its expression is related to the degree of cell differentiation.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Hepatectomy / methods. Hepatocyte Growth Factor / pharmacology. Immediate-Early Proteins / genetics. Liver Neoplasms / genetics. RNA, Messenger / metabolism. Transcriptional Activation
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Animals. Cells, Cultured. Disease Progression. Female. Hepatocytes / metabolism. Humans. Male. Microarray Analysis. Middle Aged. Rats. Rats, Wistar. Recombinant Proteins / pharmacology. Tumor Suppressor Proteins

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19502170.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / BTG2 protein, rat; 0 / Immediate-Early Proteins; 0 / RNA, Messenger; 0 / Recombinant Proteins; 0 / Tumor Suppressor Proteins; 67256-21-7 / Hepatocyte Growth Factor
  •  go-up   go-down


69. Lee KK, Kim DG, Moon IS, Lee MD, Park JH: Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma. J Surg Oncol; 2010 Jan 1;101(1):47-53
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver transplantation versus liver resection for the treatment of hepatocellular carcinoma.
  • PURPOSE: Liver resection (LR) and liver transplantation (LT) are considered the only two potentially curative treatments for hepatocellular carcinoma (HCC).
  • HCC recurred more frequently after resection (51.5%) than it did after transplantation (29.5%) (P < 0.001), and HCC recurrence developed in the liver more frequently after LR than it did after LT (P = 0.002).
  • CONCLUSION: LT should be considered as the primary treatment in patients with HCC within the Milan criteria.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Hepatectomy. Liver Neoplasms / surgery. Liver Transplantation
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Survival Rate


70. Mehrabi A, Fonouni H, Ahmadi R, Schmied BM, Müller SA, Welsch T, Hallscheidt P, Zeier M, Weitz J, Schmidt J: Transplantation of a severely lacerated liver--a case report with review of the literature. Clin Transplant; 2009 Jun-Jul;23(3):321-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transplantation of a severely lacerated liver--a case report with review of the literature.
  • Using lacerated livers for liver transplantation (LTx) can add an option to the extended donor criteria.
  • We present an LTx case using a severely lacerated liver and review of the literature for reported cases.
  • We used a high-grade lacerated liver from a 19-yr-old brain-dead patient caused by traffic accident.
  • The liver had grade IV and II lacerations in the right and left lobe, respectively.
  • The liver was transplanted to a 49-yr-old man suffering from hepatocellular carcinoma on hepatitis C-induced liver cirrhosis.
  • The liver injury ranged from subcapsular hematoma to deep ruptures.
  • The reported complications were primary non- (18%), or poor function, liver abscess, bilioma, and subhepatic hematoma each in one case (5.5%).
  • Because of complexity of the management, procurement and transplantation should be done by experienced liver surgeons.
  • [MeSH-major] Lacerations. Liver / injuries. Liver Transplantation / methods
  • [MeSH-minor] Female. Humans. Male. Middle Aged. Tissue and Organ Harvesting / methods. Young Adult

  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19537300.001).
  • [ISSN] 1399-0012
  • [Journal-full-title] Clinical transplantation
  • [ISO-abbreviation] Clin Transplant
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Number-of-references] 26
  •  go-up   go-down


71. Liang WC, Guo RP, Chen MS, Long H, Shi M, Wei W, Zhang YQ: [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis]. Ai Zheng; 2008 Mar;27(3):319-22
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of pulmonary resection for primary hepatocellular carcinoma patients with pulmonary metastasis].
  • This study was to evaluate the efficacy of pulmonary resection for primary hepatocellular carcinoma (HCC) patients with pulmonary metastasis.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Lung Neoplasms / secondary. Lung Neoplasms / surgery. Pneumonectomy
  • [MeSH-minor] Adult. Female. Humans. Male. Middle Aged. Survival Rate

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18334126.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


72. Bernal E, Montero JL, Delgado M, Fraga E, Costán G, Barrera P, López-Vallejos P, Solórzano G, Rufián S, Briceño J, Padillo J, López-Cillero P, Marchal T, Muntané J, de la Mata M: Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation. Transplant Proc; 2006 Oct;38(8):2495-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adjuvant chemotherapy for prevention of recurrence of invasive hepatocellular carcinoma after orthotopic liver transplantation.
  • Orthotopic liver transplantation (OLT) is the best treatment for nonresectable hepatocellular carcinoma (HCC), but tumor recurrence reduces long-term and medium-term survival.
  • METHODS: Three hundred eighty-seven consecutive patients, including 43 with HCC superimposed on liver cirrhosis, underwent OLT.
  • Chemotherapy was reasonably well tolerated, but the 9 patients with hepatitis C- or B-associated cirrhosis showed viral and histological recurrence of the primary disease.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Chemotherapy, Adjuvant. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Female. Humans. Middle Aged. Prognosis. Recurrence. Retrospective Studies. Survival Analysis. Time Factors


73. Chok KS, Ng KK, Cheung TT, Yuen WK, Poon RT, Lo CM, Fan ST: An update on long-term outcome of curative hepatic resection for hepatocholangiocarcinoma. World J Surg; 2009 Sep;33(9):1916-21
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: Hepatocholangiocarcinoma (HCC-CC) is a rare primary liver cancer.
  • PATIENTS AND METHODS: Prospectively collected data from December 1991 to 2006 recording patients with primary liver cancer receiving curative hepatectomy were reviewed.
  • Their long-term outcome of resection was analyzed and compared to that of patients with cholangiocarcinoma (CC) or hepatocellular carcinoma (HCC).
  • All HCC-CC patients died within 120 months of primary surgery.
  • [MeSH-major] Cholangiocarcinoma / surgery. Hepatectomy / methods. Liver Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Prospective Studies. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Arch Surg. 1995 Feb;130(2):198-203 [7848092.001]
  • [Cites] J Gastroenterol Hepatol. 1996 Aug;11(8):758-64 [8872774.001]
  • [Cites] Arch Surg. 2003 Jan;138(1):86-90 [12511158.001]
  • [Cites] Am J Pathol. 1949 Jul;25(4):647-55 [18152860.001]
  • [Cites] Int J Cancer. 2001 Oct 15;94(2):153-6 [11668491.001]
  • [Cites] Hepatol Res. 2005 Jul;32(3):185-95 [15978872.001]
  • [Cites] Br J Surg. 1997 Sep;84(9):1255-9 [9313707.001]
  • [Cites] Cancer. 1985 Jan 1;55(1):124-35 [2578078.001]
  • [Cites] Jpn J Clin Oncol. 2003 Jun;33(6):283-7 [12913082.001]
  • [Cites] Am J Surg Pathol. 1991 Mar;15(3):280-8 [1847609.001]
  • [Cites] Ann Surg. 2004 Feb;239(2):194-201 [14745327.001]
  • [Cites] J Gastrointest Surg. 2006 Jul-Aug;10(7):987-98 [16843869.001]
  • [Cites] Hepatobiliary Pancreat Dis Int. 2007 Apr;6(2):161-5 [17374575.001]
  • [Cites] Ann Surg. 1999 Feb;229(2):216-22 [10024103.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] J Gastroenterol Hepatol. 1998 Jan;13(1):34-40 [9737569.001]
  • [Cites] J Surg Oncol. 2001 Jan;76(1):37-46 [11223823.001]
  • [Cites] Ann Surg. 1999 Mar;229(3):322-30 [10077043.001]
  • [Cites] Pathol Res Pract. 1987 Dec;182(6):783-91 [2449680.001]
  • [Cites] Cancer. 2002 Apr 1;94(7):2040-6 [11932907.001]
  • (PMID = 19548027.001).
  • [ISSN] 1432-2323
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


74. Wu ZM, Liu Q, Qi XH: [Efficacy of cantharidin combined with transcatheter arterial embolization for primary hepatocellular carcinoma]. Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec;30(12):2774-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Efficacy of cantharidin combined with transcatheter arterial embolization for primary hepatocellular carcinoma].
  • [MeSH-major] Cantharidin / therapeutic use. Carcinoma, Hepatocellular / therapy. Embolization, Therapeutic. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Female. Humans. Male. Middle Aged. Portal Vein. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CANTHARIDINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21341532.001).
  • [ISSN] 1673-4254
  • [Journal-full-title] Nan fang yi ke da xue xue bao = Journal of Southern Medical University
  • [ISO-abbreviation] Nan Fang Yi Ke Da Xue Xue Bao
  • [Language] chi
  • [Publication-type] Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Chemical-registry-number] IGL471WQ8P / Cantharidin
  •  go-up   go-down


75. Lin ZY, Chuang WL, Chuang YH, Yu ML, Hsieh MY, Wang LY, Tsai JF: Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique. J Gastroenterol Hepatol; 2006 Feb;21(2):398-405
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Discordant influence of amphotericin B on epirubicin cytotoxicity in primary hepatic malignant cells collected by a new primary culture technique.
  • BACKGROUND: The purpose of this prospective study was to investigate whether amphotericin B (AmB) had any potential role in the systemic chemotherapy of primary hepatic malignancy using cancer cells collected by the authors' method of primary culture.
  • METHODS: The specimens obtained by ultrasound-guided fine-needle aspiration biopsy (22 G) from 15 patients with hepatocellular carcinoma (HCC) and one with cholangiocarcinoma were plated into culture flask without disaggregation by trypsin-ethylenediamine tetra-acetic acid solution.
  • A human HCC cell line (HA 22T/VGH) was studied for comparison.
  • RESULTS: Addition of AmB showed no influence on epirubicin cytotoxicity in two patients (one partial resistant HCC and one epirubicin-sensitive cholangiocarcinoma; 25%), augmentation of the epirubicin cytotoxicity in two patients (one total resistant HCC, partial resistant HA 22T/VGH cell line and one epirubicin-sensitive HCC; 37.5%), and decrease of epirubicin cytotoxicity in the remaining three (one partial resistant and two epirubicin-sensitive HCC; 37.5%).
  • CONCLUSIONS: Amphotericin B has a discordant influence on epirubicin cytotoxicity in primary cultured hepatic malignant cells.
  • Application of AmB in the systemic chemotherapy of primary hepatic malignancy should be limited to patients with positive AmB effect evaluated by an in vitro sensitivity test such as the present method.
  • [MeSH-major] Amphotericin B / therapeutic use. Anti-Bacterial Agents / therapeutic use. Antibiotics, Antineoplastic / adverse effects. Epirubicin / adverse effects. Liver Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Bile Ducts, Intrahepatic. Biopsy, Fine-Needle. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / pathology. Cell Culture Techniques. Cell Proliferation / drug effects. Cholangiocarcinoma / drug therapy. Cholangiocarcinoma / pathology. Drug Interactions. Drug Therapy, Combination. Female. Follow-Up Studies. Humans. Male. Middle Aged. Prospective Studies. Treatment Outcome. Tumor Cells, Cultured

  • MedlinePlus Health Information. consumer health - Antibiotics.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. AMPHOTERICIN B .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16509865.001).
  • [ISSN] 0815-9319
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents; 0 / Antibiotics, Antineoplastic; 3Z8479ZZ5X / Epirubicin; 7XU7A7DROE / Amphotericin B
  •  go-up   go-down


76. Choi BO, Choi IB, Jang HS, Kang YN, Jang JS, Bae SH, Yoon SK, Chai GY, Kang KM: Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis. BMC Cancer; 2008;8:351
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stereotactic body radiation therapy with or without transarterial chemoembolization for patients with primary hepatocellular carcinoma: preliminary analysis.
  • BACKGROUND: The objectives of this retrospective study was to evaluate the efficacy of stereotactic body radiation therapy (SBRT) for small non-resectable hepatocellular carcinoma (HCC) and SBRT combined with transarterial chemoembolization (TACE) for advanced HCC with portal vein tumor thrombosis (PVTT).
  • We studied 32 HCC lesions, where 23 lesions (22 patients) were treated targeting small non-resectable primary HCC, and 9 lesions (9 patients) targeting PVTT using the Cyberknife.
  • CONCLUSION: SBRT for small HCC and SBRT combined with TACE for advanced HCC with PVTT showed feasible treatment modalities with minimal side effects in selected patients with primary HCC.
  • [MeSH-major] Carcinoma, Hepatocellular / radiotherapy. Carcinoma, Hepatocellular / therapy. Chemoembolization, Therapeutic / methods. Liver Neoplasms / surgery. Liver Neoplasms / therapy. Radiosurgery / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Retrospective Studies. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Aug 1;48(1):81-7 [10924975.001]
  • [Cites] Hepatology. 2008 Jan;47(1):71-81 [18027884.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):164-70 [11134209.001]
  • [Cites] Eur J Ultrasound. 2001 Jun;13(2):149-58 [11369526.001]
  • [Cites] J Gastroenterol Hepatol. 2001 Jun;16(6):660-5 [11422619.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):522-31 [11872300.001]
  • [Cites] Gastroenterology. 2002 May;122(6):1609-19 [12016426.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Sep 1;54(1):150-5 [12182985.001]
  • [Cites] Neurosurgery. 2003 Jan;52(1):140-6; discussion 146-7 [12493111.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Sep 1;57(1):113-9 [12909223.001]
  • [Cites] Radiology. 1983 Aug;148(2):397-401 [6306721.001]
  • [Cites] Radiother Oncol. 1983 Nov;1(2):187-91 [6680223.001]
  • [Cites] J Clin Oncol. 2008 Feb 1;26(4):657-64 [18172187.001]
  • [Cites] Cancer. 1985 Aug 15;56(4):918-28 [2990661.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 May 15;21(1):109-22 [2032882.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Nov;21(6):1425-34 [1938550.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1995 Mar 30;31(5):1249-56 [7713786.001]
  • [Cites] Scand J Gastroenterol. 1997 Jun;32(6):598-603 [9200294.001]
  • [Cites] Hepatology. 1998 Jun;27(6):1578-83 [9620330.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Oct 1;63(2):320-3 [16168826.001]
  • [Cites] Semin Radiat Oncol. 2005 Oct;15(4):273-8 [16183481.001]
  • [Cites] World J Gastroenterol. 2005 Dec 21;11(47):7391-400 [16437707.001]
  • [Cites] Jpn J Clin Oncol. 2006 Mar;36(3):154-8 [16520355.001]
  • [Cites] Cancer. 2006 Apr 15;106(8):1653-63 [16541431.001]
  • [Cites] Acta Oncol. 2006;45(7):961-5 [16982564.001]
  • [Cites] J Clin Oncol. 2007 Mar 10;25(8):938-46 [17350942.001]
  • [Cites] J Am Coll Radiol. 2007 Aug;4(8):563-5 [17660122.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1187-95 [11072178.001]
  • (PMID = 19038025.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2615783
  •  go-up   go-down


77. Dollinger MM, Lautenschlaeger C, Lesske J, Tannapfel A, Wagner AD, Schoppmeyer K, Nehls O, Welker MW, Wiest R, Fleig WE, AIO Hepatobiliary Study Group: Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer; 2010;10:457
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial.
  • BACKGROUND: Thymostimulin is a thymic peptide fraction with immune-mediated cytotoxicity against hepatocellular carcinoma (HCC) in vitro and palliative efficacy in advanced HCC in two independent phase II trials.
  • 5x/week or placebo stratified according to liver function.
  • Primary endpoint was twelve-month survival, secondary endpoints overall survival (OS), time to progression (TTP), tumor response, safety and quality of life.
  • A subgroup analysis according to liver function, KPS and tumor stage (Okuda, CLIP and BCLC) formed part of the protocol.
  • Adjustment for liver function, Karnofsky status or tumor stage did not affect results.
  • [MeSH-major] Carcinoma, Hepatocellular / drug therapy. Interferon Inducers / therapeutic use. Liver Neoplasms / drug therapy. Thymus Extracts / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Disease Progression. Double-Blind Method. Female. Follow-Up Studies. Humans. Male. Middle Aged. Neoplasm Staging. Palliative Care. Placebos. Prospective Studies. Survival Rate. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Anticancer Res. 1989 Jan-Feb;9(1):193-6 [2539772.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] Ann Surg Oncol. 1997 Mar;4(2):149-55 [9084852.001]
  • [Cites] Hepatogastroenterology. 1998 Jan-Feb;45(19):209-15 [9496515.001]
  • [Cites] Semin Liver Dis. 2005;25(2):201-11 [15918148.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:326-38 [17495242.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:297-304 [17567944.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:357-67 [17600289.001]
  • [Cites] Ann N Y Acad Sci. 2007 Sep;1112:225-34 [17600290.001]
  • [Cites] BMC Cancer. 2008;8:72 [18366627.001]
  • [Cites] J Natl Cancer Inst. 2008 May 21;100(10):698-711 [18477802.001]
  • [Cites] N Engl J Med. 2008 Jul 24;359(4):378-90 [18650514.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] J Clin Oncol. 2002 May 1;20(9):2229-39 [11980994.001]
  • [Cites] Z Gastroenterol. 2003 Nov;41(11):1101-10 [14648380.001]
  • [Cites] Lancet Oncol. 2004 Jul;5(7):409-18 [15231247.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16 [15508102.001]
  • [Cites] Immunopharmacol Immunotoxicol. 1992;14(3):421-37 [1325490.001]
  • (PMID = 20735834.001).
  • [ISSN] 1471-2407
  • [Journal-full-title] BMC cancer
  • [ISO-abbreviation] BMC Cancer
  • [Language] eng
  • [Databank-accession-numbers] ISRCTN/ ISRCTN64487365
  • [Publication-type] Clinical Trial, Phase III; Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Interferon Inducers; 0 / Placebos; 0 / Thymus Extracts; 0 / thymostimulin
  • [Other-IDs] NLM/ PMC2936330
  • [Investigator] Lesske J; Dollinger MM; Fleig WE; Schoppmeyer K; Mössner J; Nehls O; Gregor M; Welker MW; Zeuzem S; Wiest R; Schoelmerich J; Hummel F; Singer M; Seufferlein T; Adler G; Mohr L; Spangenberg HC; Blum H; Pohl M; Schmiegel W; Gog C; Bechstein W; Schaefer C; Stange E; Lammert F; Matern S
  •  go-up   go-down


78. Muth A, Persson F, Jansson S, Johanson V, Ahlman H, Wängberg B: Prognostic factors for survival after surgery for adrenal metastasis. Eur J Surg Oncol; 2010 Jul;36(7):699-704
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: A consecutive series of 30 patients undergoing adrenalectomy for metastasis (1996-2007), excluding patients with simultaneous ipsilateral renal cell carcinoma (RCC), was studied.
  • Metastases were regarded as synchronous (<6 mo), or metachronous (>6 mo), depending on the interval after primary surgery.
  • RESULTS: The tumour diagnoses were RCC n = 9, malignant melanoma n = 5, non-small-cell lung cancer n = 5, colorectal carcinoma n = 4, foregut carcinoid n = 2, adrenocortical carcinoma, breast cancer, hepatocellular carcinoma, urothelial carcinoma, and liposarcoma (one each); nine adrenal metastases were synchronous and 21 metachronous.
  • Independent prognosticators of favourable survival were adrenalectomy for potential cure (p = 0.01), no previous metastasis surgery (p = 0.02), and tumour type (p = 0.043), with better prognosis for patients with adrenal metastasis from colorectal carcinoma and RCC and worse prognosis in non-small-cell lung cancer and malignant melanoma.
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Kaplan-Meier Estimate. Laparoscopy. Male. Middle Aged. Neoplasm Staging. Predictive Value of Tests. Prognosis. Retrospective Studies. Risk Factors. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20452170.001).
  • [ISSN] 1532-2157
  • [Journal-full-title] European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
  • [ISO-abbreviation] Eur J Surg Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


79. Xu J, Chen X: Expression of twist gene in primary liver cancer. J Huazhong Univ Sci Technolog Med Sci; 2007 Dec;27(6):668-70
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of twist gene in primary liver cancer.
  • In order to investigate the possibility of overexpression of Twist in primary liver cancer (PLC), the Twist expression was detected by using immunohistochemical analysis and RT-PCR assay in 45 patients with PLC.
  • Control tissues were obtained from 9 patients with liver hemangioma.
  • In noncancerous adjacent areas and control liver tissues, the expression of Twist was 57.8% and 22.2% respectively.
  • [MeSH-major] Carcinoma, Hepatocellular / genetics. Liver Neoplasms / genetics. Nuclear Proteins / genetics. Twist-Related Protein 1 / genetics
  • [MeSH-minor] Adult. Aged. Female. Humans. Immunohistochemistry. Male. Middle Aged. Reverse Transcriptase Polymerase Chain Reaction. Up-Regulation. Young Adult

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1906-13 [12702582.001]
  • [Cites] Nat Genet. 1997 Jan;15(1):42-6 [8988167.001]
  • [Cites] Dev Biol. 1995 Nov;172(1):280-92 [7589808.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Jan 3;300(1):178-81 [12480539.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] J Biol Chem. 2005 Jan 21;280(3):2294-9 [15545268.001]
  • [Cites] Hum Mutat. 2005 Jun;25(6):550-6 [15880747.001]
  • [Cites] Mol Cell Biol. 2001 Nov;21(21):7416-28 [11585922.001]
  • [Cites] Nucleic Acids Res. 1987 Apr 24;15(8):3439-53 [3106932.001]
  • [Cites] Clin Genet. 2004 May;65(5):396-9 [15099347.001]
  • [Cites] Ann Surg Oncol. 2005 Jun;12 (6):488-96 [15864483.001]
  • [Cites] Genes Dev. 1995 Mar 15;9(6):686-99 [7729687.001]
  • [Cites] Nature. 2000 Sep 14;407(6801):249-57 [11001068.001]
  • [Cites] Cell. 2003 Jan 24;112(2):169-80 [12553906.001]
  • [Cites] J Clin Invest. 2002 Sep;110(5):633-41 [12208864.001]
  • [Cites] Nat Med. 2003 Jun;9(6):653-60 [12778163.001]
  • [Cites] Dev Biol. 1997 Sep 15;189(2):205-14 [9299114.001]
  • [Cites] Genes Dev. 1999 Sep 1;13(17 ):2207-17 [10485844.001]
  • [Cites] Am J Pathol. 2002 Nov;161(5):1881-91 [12414534.001]
  • (PMID = 18231738.001).
  • [ISSN] 1672-0733
  • [Journal-full-title] Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban
  • [ISO-abbreviation] J. Huazhong Univ. Sci. Technol. Med. Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Nuclear Proteins; 0 / TWIST1 protein, human; 0 / Twist-Related Protein 1
  •  go-up   go-down


80. Liang P, Dong BW, Yu XL, Yu DJ, Feng L, Gao YY, Wang Y, Xiao QJ: [Evaluation of long-term therapeutic effects of ultrasound-guided percutaneous microwave ablation of liver metastases]. Zhonghua Yi Xue Za Zhi; 2006 Mar 28;86(12):806-10
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Evaluation of long-term therapeutic effects of ultrasound-guided percutaneous microwave ablation of liver metastases].
  • METHODS: From July 1995 to June 2005 128 patients with 282 hepatic metastases nodules with the primary diseases of upper gastrointestinal tumor (n = 26), colorectal tumor (n = 44), breast carcinoma (n = 19), pulmonary carcinoma (n = 15), and malignant tumor in other part of the body (n = 24), underwent percutaneous microwave ablation therapy and were followed up for 29.7 +/- 19.9 months (1 - 103 months).
  • [MeSH-major] Carcinoma, Hepatocellular / therapy. Catheter Ablation / methods. Liver Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Prognosis. Proportional Hazards Models. Time Factors. Ultrasonography, Interventional

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16681966.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  •  go-up   go-down


81. Wang B, Tian HQ, Liang GW: [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer]. Zhongguo Zhong Xi Yi Jie He Za Zhi; 2009 Mar;29(3):257-60
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Effect of ganji recipe combined with Fructus Bruceae oil emulsion intervention on quality of life in patients with advanced primary hepatic cancer].
  • OBJECTIVE: To observe and compare the quality of life (QOL) and survival time in patients with advanced primary hepatic cancer (PHC) after they have been treated by the combination of ganji recipe and interventional therapy with Fructus Bruceae Oil Emulsion (FBE) or by the trans-hepatic arterial chemical embolization (TACE) adopting Seldinger's technique.

  • MedlinePlus Health Information. consumer health - Herbal Medicine.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19548447.001).
  • [ISSN] 1003-5370
  • [Journal-full-title] Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine
  • [ISO-abbreviation] Zhongguo Zhong Xi Yi Jie He Za Zhi
  • [Language] CHI
  • [Publication-type] English Abstract; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Drugs, Chinese Herbal; 0 / Plant Oils
  •  go-up   go-down


82. Song I, Rhim H, Lim HK, Kim YS, Choi D: Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients. Eur Radiol; 2009 Nov;19(11):2630-40
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous radiofrequency ablation of hepatocellular carcinoma abutting the diaphragm and gastrointestinal tracts with the use of artificial ascites: safety and technical efficacy in 143 patients.
  • The purpose of this study was to assess the feasibility, safety and efficacy of radiofrequency ablation (RFA) with the use of artificial ascites for hepatocellular carcinoma (HCC) adjacent to the diaphragm and gastrointestinal tract.
  • The technical success rate, as well as the primary and secondary technique success rate, was assessed by regular follow-up CT examinations.
  • The primary technique effectiveness was 85.3%.
  • [MeSH-major] Ascites / pathology. Carcinoma, Hepatocellular / radiotherapy. Catheter Ablation / methods. Liver Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Female. Follow-Up Studies. Humans. Male. Middle Aged. Necrosis. Time Factors. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] AJR Am J Roentgenol. 2004 May;182(5):1224-6 [15100123.001]
  • [Cites] Ann Surg Oncol. 2000 Sep;7(8):593-600 [11005558.001]
  • [Cites] J Vasc Interv Radiol. 2002 Mar;13(3):313-5 [11875091.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] Br J Surg. 2006 Oct;93(10):1277-82 [16783759.001]
  • [Cites] Ann Surg. 1999 Jun;229(6):790-9; discussion 799-800 [10363892.001]
  • [Cites] Gastroenterology. 2005 Jul;129(1):122-30 [16012942.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Hepatology. 2002 Mar;35(3):519-24 [11870363.001]
  • [Cites] J Gastroenterol. 2007 Apr;42(4):306-11 [17464460.001]
  • [Cites] Radiology. 2003 Jul;228(1):235-40 [12759473.001]
  • [Cites] Br J Surg. 2008 Aug;95(8):996-1004 [18581421.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Abdom Imaging. 2009 May-Jun;34(3):371-80 [18463915.001]
  • [Cites] AJR Am J Roentgenol. 2004 Sep;183(3):583-8 [15333339.001]
  • [Cites] Radiology. 2007 Jun;243(3):877-84 [17517940.001]
  • [Cites] Radiology. 2008 Aug;248(2):670-9 [18519740.001]
  • [Cites] Eur J Surg Oncol. 2005 May;31(4):331-47 [15837037.001]
  • [Cites] Gut. 2005 Aug;54(8):1151-6 [16009687.001]
  • [Cites] Gastroenterology. 2004 Nov;127(5 Suppl 1):S248-60 [15508091.001]
  • [Cites] Hepatology. 1992 May;15(5):948-63 [1314774.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):817-8 [11222239.001]
  • [Cites] J Vasc Interv Radiol. 2003 Sep;14 (9 Pt 1):1183-6 [14514811.001]
  • [Cites] Abdom Imaging. 2008 Jul-Aug;33(4):428-36 [17639375.001]
  • [Cites] Radiographics. 2004 Jan-Feb;24(1):41-52 [14730035.001]
  • [Cites] AJR Am J Roentgenol. 2003 Jun;180(6):1561-2 [12760919.001]
  • [Cites] Cardiovasc Intervent Radiol. 2003 May-Jun;26(3):302-4 [14562984.001]
  • [Cites] Hepatology. 2008 Jan;47(1):82-9 [18008357.001]
  • [Cites] Radiology. 2002 Mar;222(3):819-23 [11867807.001]
  • [Cites] Cancer Treat Rev. 2007 Aug;33(5):437-47 [17512669.001]
  • [Cites] J Gastroenterol. 2003;38(11):1066-70 [14673724.001]
  • [Cites] AJR Am J Roentgenol. 2004 Jul;183(1):197-200 [15208138.001]
  • [Cites] AJR Am J Roentgenol. 1999 Jan;172(1):65-6 [9888741.001]
  • [Cites] AJR Am J Roentgenol. 2008 Jan;190(1):91-8 [18094298.001]
  • [Cites] Radiology. 1999 Mar;210(3):655-61 [10207464.001]
  • [Cites] J Vasc Interv Radiol. 2006 Mar;17 (3):541-7 [16567679.001]
  • [Cites] Gastroenterology. 1978 Jan;74(1):103-6 [618417.001]
  • [Cites] J Vasc Interv Radiol. 2005 Mar;16(3):407-10 [15758140.001]
  • (PMID = 19557416.001).
  • [ISSN] 1432-1084
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


83. Tang W, Kokudo N, Sugawara Y, Guo Q, Imamura H, Sano K, Karako H, Qu X, Nakata M, Makuuchi M: Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma. Oncol Rep; 2005 Jan;13(1):25-30
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma.
  • The level of serum DCP is used in clinical diagnosis and prognosis of patients with hepatocellular carcinoma (HCC).
  • A retrospective study was performed of 132 patients each with a single primary HCC nodule.
  • [MeSH-major] Biomarkers / metabolism. Carcinoma, Hepatocellular / mortality. Carcinoma, Hepatocellular / surgery. Liver / metabolism. Liver Neoplasms / mortality. Liver Neoplasms / surgery. Protein Precursors / metabolism. Prothrombin / metabolism
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Biomarkers, Tumor / analysis. Biomarkers, Tumor / metabolism. Female. Humans. Male. Middle Aged. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Liver cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15583797.001).
  • [ISSN] 1021-335X
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Biomarkers; 0 / Biomarkers, Tumor; 0 / Protein Precursors; 53230-14-1 / acarboxyprothrombin; 9001-26-7 / Prothrombin
  •  go-up   go-down


84. Kobayashi N, Hiraoka N, Yamagami W, Ojima H, Kanai Y, Kosuge T, Nakajima A, Hirohashi S: FOXP3+ regulatory T cells affect the development and progression of hepatocarcinogenesis. Clin Cancer Res; 2007 Feb 1;13(3):902-11
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • EXPERIMENTAL DESIGN: We examined the infiltration of FOXP3+ Tregs and CD8+ T cells in the tumor stroma and nontumorous liver parenchyma using 323 hepatic nodules including precursor lesions, early hepatocellular carcinoma (HCC), and advanced HCC, along with 39 intrahepatic cholangiocarcinomas and 59 metastatic liver adenocarcinomas.
  • RESULTS: The prevalence of Tregs was significantly higher in HCC than in the nontumorous liver (P<0.001).
  • Regardless of the presence of hepatitis virus infection or histopathologic evidence of hepatitis, the prevalence of Tregs was significantly increased in nontumorous liver bearing primary hepatic tumors.
  • It has been suggested that primary hepatic cancers develop in liver that is immunosuppressed by a marked infiltration of Tregs.
  • [MeSH-major] Carcinoma, Hepatocellular / metabolism. Forkhead Transcription Factors / biosynthesis. Liver Neoplasms / metabolism. T-Lymphocytes, Regulatory / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. CD8-Positive T-Lymphocytes / metabolism. Cholangiocarcinoma / metabolism. Disease Progression. Female. Humans. Immunohistochemistry. Male. Middle Aged. Neoplasm Metastasis

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • The Lens. Cited by Patents in .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17289884.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXP3 protein, human; 0 / Forkhead Transcription Factors
  •  go-up   go-down


85. Wu MH, Lin MT, Lee PH: Clinicopathological study of gastric metastases. World J Surg; 2007 Jan;31(1):132-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVE: The stomach is an uncommon site for metastasis, and most of the reported examples would appear to have been caused by direct invasion from primary malignancies.
  • The time period elapsing between the emergence of the primary malignancy and the gastric metastasis was less than 2 years for 3 patients and about 5-6 years for another 2 patients.
  • [MeSH-minor] Adenocarcinoma / secondary. Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / secondary. Female. Gastrectomy. Humans. Liver Neoplasms / pathology. Lung Neoplasms / pathology. Male. Middle Aged. Prognosis. Retrospective Studies

  • MedlinePlus Health Information. consumer health - Stomach Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Gastric Cancer. 2006;9(1):19-25 [16557432.001]
  • [Cites] Cancer. 1990 Apr 1;65(7):1596-600 [2311070.001]
  • [Cites] J Clin Gastroenterol. 1981;3 Suppl 1:35-7 [7328295.001]
  • [Cites] Can J Surg. 1962 Oct;5:438-41 [13954414.001]
  • [Cites] Am J Dig Dis. 1975 Oct;20(10 ):903-13 [1190198.001]
  • [Cites] J Gastroenterol. 2005 Feb;40(2):209-12 [15770407.001]
  • [Cites] Am J Surg. 1960 Jan;99:94-6 [13814449.001]
  • [Cites] Eur J Radiol. 1983 Nov;3(4):331-8 [6653567.001]
  • [Cites] J Gastroenterol Hepatol. 2000 May;15(5):536-41 [10847441.001]
  • [Cites] J Am Coll Surg. 2002 Sep;195(3):311-8 [12229937.001]
  • [Cites] Radiol Clin North Am. 1993 Nov;31(6):1359-73 [8210355.001]
  • (PMID = 17186432.001).
  • [ISSN] 0364-2313
  • [Journal-full-title] World journal of surgery
  • [ISO-abbreviation] World J Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


86. Lim EJ, Gow PJ, Angus PW: Endoscopic variceal ligation for primary prophylaxis of esophageal variceal hemorrhage in pre-liver transplant patients. Liver Transpl; 2009 Nov;15(11):1508-13
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoscopic variceal ligation for primary prophylaxis of esophageal variceal hemorrhage in pre-liver transplant patients.
  • This study included 300 adult patients with cirrhosis on our liver transplant waitlist who underwent upper gastrointestinal endoscopy.
  • This study shows that in liver transplant candidates, EVL is highly effective in preventing first variceal bleed.
  • [MeSH-major] Endoscopy / methods. Esophageal and Gastric Varices / surgery. Gastrointestinal Hemorrhage / prevention & control. Liver Transplantation. Preoperative Care
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Hepatocellular / surgery. Female. Humans. Ligation. Liver Neoplasms / surgery. Male. Medical Audit. Middle Aged. Postoperative Complications / etiology. Postoperative Complications / prevention & control. Retrospective Studies. Treatment Outcome. Waiting Lists. Young Adult


87. Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y: Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF. Ann Clin Lab Sci; 2007;37(1):39-48
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinomas: analysis using tissue microarrays and comparisons with CD34 and VEGF.
  • Few studies about angiogenesis in hepatocellular carcinoma (HCC) have been conducted and little is known about the significance of angiogenesis in HCC.
  • [MeSH-major] Antigens, CD / metabolism. Biomarkers / metabolism. Carcinoma, Hepatocellular / metabolism. Liver Neoplasms / metabolism. Neovascularization, Pathologic / metabolism. Receptors, Cell Surface / metabolism
  • [MeSH-minor] Adult. Antigens, CD34 / metabolism. China. Evaluation Studies as Topic. Female. Humans. Immunohistochemistry. Male. Microarray Analysis / methods. Middle Aged. Prognosis. Survival Analysis. Vascular Endothelial Growth Factor A / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311868.001).
  • [ISSN] 0091-7370
  • [Journal-full-title] Annals of clinical and laboratory science
  • [ISO-abbreviation] Ann. Clin. Lab. Sci.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD; 0 / Antigens, CD34; 0 / Biomarkers; 0 / ENG protein, human; 0 / Receptors, Cell Surface; 0 / VEGFA protein, human; 0 / Vascular Endothelial Growth Factor A
  •  go-up   go-down


88. Mazzaferro V, Romito R, Schiavo M, Mariani L, Camerini T, Bhoori S, Capussotti L, Calise F, Pellicci R, Belli G, Tagger A, Colombo M, Bonino F, Majno P, Llovet JM, HCC Italian Task Force: Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology; 2006 Dec;44(6):1543-54
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis.
  • Tumor recurrence after resection of hepatocellular carcinoma (HCC) can occur early (<2 years) or late (>2 years) as metastases or de novo tumors.
  • The primary end point was recurrence-free survival (RFS); secondary end points were disease-specific and overall survival.
  • [MeSH-major] Carcinoma, Hepatocellular / prevention & control. Hepatitis C, Chronic / drug therapy. Interferon-alpha / therapeutic use. Liver Cirrhosis / drug therapy. Liver Neoplasms / prevention & control. Neoplasm Recurrence, Local / prevention & control
  • [MeSH-minor] Adult. Aged. Comorbidity. Female. Hepatectomy. Hepatitis B Core Antigens / analysis. Hepatitis B, Chronic / complications. Humans. Male. Middle Aged. Multivariate Analysis. Recombinant Proteins. Risk. alpha-Fetoproteins / analysis


89. Ikeda K, Arase Y, Saitoh S, Kobayashi M, Someya T, Hosaka T, Akuta N, Suzuki Y, Suzuki F, Sezaki H, Kumada H, Tanaka A, Harada H: Prediction model of hepatocarcinogenesis for patients with hepatitis C virus-related cirrhosis. Validation with internal and external cohorts. J Hepatol; 2006 Jun;44(6):1089-97
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RESULTS: The carcinogenesis rates in the primary cohort were 28.9% at the 5th year and 54.0% at the 10th year.
  • [MeSH-major] Carcinoma, Hepatocellular / epidemiology. Hepatitis C / complications. Liver Cirrhosis / complications. Liver Neoplasms / epidemiology. Models, Biological
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Cohort Studies. Female. Humans. Incidence. Japan / epidemiology. Male. Middle Aged. Prognosis. Reproducibility of Results


90. Morise Z, Sugioka A, Fujita J, Hoshimoto S, Kato T, Ikeda M: S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas. Hepatogastroenterology; 2007 Dec;54(80):2315-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] S-1 plus cisplatin combination therapy for the patients with primary liver carcinomas.
  • BACKGROUND/AIMS: 5-FU plus Cisplatin combination therapy had been employed against primary liver carcinomas for years.
  • We herein examined the effect and adverse effects of S-1 plus Cisplatin combination therapy for primary liver carcinomas.
  • METHODOLOGY: 4 patients with hepatocellular carcinoma (HCC) and 3 with cholangiocellular carcinoma (CCC) were employed for this study.
  • They all had far-advanced diseases in and/or out of the liver at the time of the therapy initiation.
  • CONCLUSIONS: S-1 plus Cisplatin combination therapy is a potential therapy for advanced primary liver carcinomas.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Hepatocellular / drug therapy. Liver Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Drug Combinations. Female. Humans. Lung Neoplasms / secondary. Male. Middle Aged. Oxonic Acid / administration & dosage. Prognosis. Tegafur / administration & dosage. Tomography, X-Ray Computed

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18265655.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


91. Vitale A, Boccagni P, Brolese A, Neri D, Srsen N, Zanus G, Pagano D, Pauletto A, Bonsignore P, Scopelliti M, D'Amico FE, Ometto G, Polacco M, Burra P, Gambato M, Feltracco P, Romano A, Cillo U: Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation? Transplant Proc; 2009 May;41(4):1264-7
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Progression of hepatocellular carcinoma before liver transplantation: dropout or liver transplantation?
  • BACKGROUND: Tumor progression before liver transplantation (OLT) is the main cause of dropout from the waiting list (WL) of patients with hepatocellular carcinoma (HCC).
  • Adult patients with benign chronic liver disease enlisted for primary OLT in the same period represented the control group.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Liver Neoplasms / pathology. Patient Dropouts
  • [MeSH-minor] Adult. Aged. Disease Progression. Female. Humans. Male. Middle Aged. Waiting Lists. Young Adult


92. Trivedi P, Gupta A, Pasricha S, Agrawal G, Shah M: Isolated skull base metastasis as the first manifestation of hepatocellular carcinoma--a rare case report with review of literature. J Gastrointest Cancer; 2009;40(1-2):10-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Isolated skull base metastasis as the first manifestation of hepatocellular carcinoma--a rare case report with review of literature.
  • INTRODUCTION: Hepatocellular carcinoma rarely metastasizes to skull base.
  • DISCUSSION: The biopsy specimen of skull base lytic lesion suggested metastatic hepatocellular carcinoma.
  • Subsequent examination revealed a large mass involving superior segment of right lobe of liver, which was confirmed as hepatocellular carcinoma on histopathological examination.
  • CONCLUSION: Until now, there have been only 24 cases of hepatocellular carcinoma metastasizing to skull base cited in literature.
  • We report here an unusual case of solitary skull base metastasis from hepatocellular carcinoma prior to the diagnosis of primary tumor.
  • [MeSH-major] Carcinoma, Hepatocellular / secondary. Liver Neoplasms / pathology. Skull Base Neoplasms / pathology
  • [MeSH-minor] Adult. Humans. Magnetic Resonance Imaging. Male

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Korean J Gastroenterol. 2008 Dec;52(6):389-93 [19096257.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1981 Dec;44(12):1171-2 [6278095.001]
  • [Cites] Neurol Med Chir (Tokyo). 1992 Mar;32(3):166-8 [1377801.001]
  • [Cites] Hong Kong Med J. 2002 Feb;8(1):48-51 [11861994.001]
  • [Cites] Neurol Med Chir (Tokyo). 1993 Dec;33(12):839-44 [7512232.001]
  • [Cites] Radiology. 1986 Jul;160(1):175-8 [3012630.001]
  • [Cites] Taiwan Yi Xue Hui Za Zhi. 1979 Jun;78(6):594-604 [226652.001]
  • [Cites] Surg Neurol. 1985 Jan;23(1):41-8 [2981120.001]
  • [Cites] Bull Soc Med Afr Noire Lang Fr. 1968;13(3):577-85 [4306564.001]
  • [Cites] Radiology. 2000 Sep;216(3):698-703 [10966697.001]
  • [Cites] J Gastroenterol Hepatol. 1995 Jul-Aug;10 (4):413-8 [8527707.001]
  • [Cites] Skull Base Surg. 2000;10(2):81-6 [17171106.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2001 Sep;13(9):1083-8 [11564960.001]
  • [Cites] HNO. 2001 Feb;49(2):126-9 [11270194.001]
  • [Cites] Neurol Med Chir (Tokyo). 1985 Mar;25(3):229-34 [2409470.001]
  • [Cites] World J Gastroenterol. 2006 Nov 7;12(41):6727-9 [17075993.001]
  • [Cites] J Neurooncol. 2005 Oct;75(1):63-9 [16215817.001]
  • [Cites] Neurosurgery. 1990 May;26(5):863-6 [2162018.001]
  • [Cites] Eur J Neurol. 2007 Apr;14(4):408-12 [17388989.001]
  • [Cites] J Surg Oncol. 1988 Sep;39(1):33-4 [2843717.001]
  • [Cites] Acta Neurochir (Wien). 2007 Feb;149(2):185-90 [17180305.001]
  • [Cites] J Neurol Neurosurg Psychiatry. 1992 Nov;55(11):1037-9 [1335033.001]
  • (PMID = 19705301.001).
  • [ISSN] 1941-6636
  • [Journal-full-title] Journal of gastrointestinal cancer
  • [ISO-abbreviation] J Gastrointest Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 27
  •  go-up   go-down


93. Tang TJ, Vukosavljevic D, Janssen HL, Binda RS, Mancham S, Tilanus HW, Ijzermans JN, Drexhage H, Kwekkeboom J: Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol; 2006 Mar;37(3):332-8
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma.
  • Patients with hepatocellular carcinoma (HCC) are characterized by a weak T-cell response to their tumor, and chronic carriers of hepatitis B virus or hepatitis C virus have a poor T-cell response against the virus.
  • These inadequate T-cell responses may be due to insufficient activation of the T cells by dendritic cells (DCs).
  • Because lymph nodes (LNs) are the primary site of antigen-specific T-cell activation, we hypothesized that hepatic LNs of patients with HCC and/or chronic viral hepatitis might have aberrant compositions of their DC populations.
  • Patients with HCC and chronic viral hepatitis and patients with chronic viral hepatitis without HCC were compared with patients with liver inflammation of nonviral etiology and with organ donors with healthy livers.
  • The numbers of PDCs and mature MDCs in hepatic LNs of patients with chronic viral hepatitis did not differ from those of patients with liver inflammation of nonviral etiology nor from individuals with healthy livers.
  • However, hepatic LNs of patients with HBV or HCV infection complicated by HCC showed a 1.5-fold reduction in numbers of mature MDCs and a 4-fold increase in numbers of PDCs in their T-cell areas compared with those of patients with viral hepatitis only (P <.01).
  • This may be one of the causes of the inadequate T-cell response against HCC in these patients.
  • [MeSH-major] Carcinoma, Hepatocellular / pathology. Dendritic Cells / pathology. Hepatitis B, Chronic / pathology. Hepatitis C, Chronic / pathology. Liver Neoplasms / pathology. Lymph Nodes / pathology
  • [MeSH-minor] Adolescent. Adult. Aged. Cell Count. Child. DNA, Viral / blood. Female. Hepacivirus / genetics. Hepacivirus / isolation & purification. Hepatitis B virus / genetics. Hepatitis B virus / isolation & purification. Humans. Male. Middle Aged. RNA, Viral / blood

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16613328.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA, Viral; 0 / RNA, Viral
  •  go-up   go-down


94. Witters P, Maleux G, George C, Delcroix M, Hoffman I, Gewillig M, Verslype C, Monbaliu D, Aerts R, Pirenne J, Van Steenbergen W, Nevens F, Fevery J, Cassiman D: Congenital veno-venous malformations of the liver: widely variable clinical presentations. J Gastroenterol Hepatol; 2008 Aug;23(8 Pt 2):e390-4
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Congenital veno-venous malformations of the liver: widely variable clinical presentations.
  • RESULTS: One patient, a 25-year-old male, had extrahepatic shunting whereby the liver receives only arterial blood because the portal vein (PV) connects with the inferior caval vein (ICV) (Abernethy Ib); he presented with episodes of jaundice and pruritus.
  • -)pulmonary hypertension without portal hypertension, and a 33-year-old female with epidsodes of acute pain secondary to spontaneous bleeding within a primary liver tumor.
  • Two patients had intrahepatic shunting; these included an 8-year-old boy who was diagnosed incidentally during work-up for abnormal liver enzymes with a communication between right PV and ICV (Park type 1), and a 59-year-old male with multiple PV-ICV-shunts in several liver segments (Park, type 4) who presented with hepatic encephalopathy.
  • CONCLUSION: Patients often present with signs of hepatic shunting (encephalopathy, pulmonary hypertension, hepatopulmonary syndrome, and/or hypoglycemia) with relative sparing of the synthetic liver function in the absence of portal hypertension.
  • Some shunts present with space-occupying lesions (focal nodular hyperplasia, hepatocellular carcinoma, nodular regenerative hyperplasia, etc.) or biliary atresia.
  • [MeSH-major] Hepatic Veins / abnormalities. Liver / blood supply. Portal Vein / abnormalities. Vascular Malformations / diagnosis
  • [MeSH-minor] Adolescent. Adult. Aged. Child. Female. Humans. Male. Middle Aged

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17868331.001).
  • [ISSN] 1440-1746
  • [Journal-full-title] Journal of gastroenterology and hepatology
  • [ISO-abbreviation] J. Gastroenterol. Hepatol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


95. Terraz S, Constantin C, Majno PE, Spahr L, Mentha G, Becker CD: Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results. Eur Radiol; 2007 Sep;17(9):2253-61
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Image-guided multipolar radiofrequency ablation of liver tumours: initial clinical results.
  • The local effectiveness and clinical usefulness of multipolar radiofrequency (RF) ablation of liver tumours was evaluated.
  • There were 45 hepatocellular carcinomas (HCC) and 42 metastases with a diameter < or =3 cm (n = 55), 3.1-5 cm (n = 29) and >5 cm (n = 3); 26 nodules were within 5 mm from large vessels.
  • The primary and secondary technical effectiveness rate was 82% and 95%, respectively.
  • Multipolar RF technique creates ablation zones of adequate size and tailored shape and is effective to treat most liver tumours, including those close to major hepatic vessels.
  • [MeSH-major] Carcinoma, Hepatocellular / surgery. Catheter Ablation / methods. Liver Neoplasms / surgery. Magnetic Resonance Imaging, Interventional. Radiography, Interventional
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Contrast Media. Disease Progression. Female. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Postoperative Complications. Statistics, Nonparametric. Survival Rate. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiology. 2006 Mar;238(3):881-90 [16424244.001]
  • [Cites] Ann Surg Oncol. 2005 Aug;12(8):616-28 [15965731.001]
  • [Cites] Radiology. 2005 Jun;235(3):728-39 [15845798.001]
  • [Cites] Eur Radiol. 2005 Apr;15(4):798-808 [15711846.001]
  • [Cites] Eur J Gastroenterol Hepatol. 2006 Jan;18(1):89-92 [16357626.001]
  • [Cites] Radiology. 2003 Feb;226(2):441-51 [12563138.001]
  • [Cites] Acad Radiol. 1996 May;3(5):418-22 [8796695.001]
  • [Cites] AJR Am J Roentgenol. 2002 Jan;178(1):47-51 [11756085.001]
  • [Cites] Hepatology. 2006 May;43(5):1101-8 [16628706.001]
  • [Cites] Med Biol Eng Comput. 2003 May;41(3):317-23 [12803297.001]
  • [Cites] Eur Radiol. 2004 Dec;14(12):2261-7 [15599547.001]
  • [Cites] Cancer. 2005 Mar 15;103(6):1201-9 [15690326.001]
  • [Cites] Eur Radiol. 2003 Oct;13(10):2346-52 [12942277.001]
  • [Cites] Radiology. 2006 Oct;241(1):116-24 [16928978.001]
  • [Cites] J Hepatol. 2001 Sep;35(3):421-30 [11592607.001]
  • [Cites] Radiology. 2005 Mar;234(3):961-7 [15665226.001]
  • [Cites] Eur Radiol. 2006 Mar;16(3):661-9 [16228211.001]
  • [Cites] Liver Transpl. 2004 Feb;10 (2 Suppl 1):S98-106 [14762848.001]
  • [Cites] J Vasc Interv Radiol. 1998 Jan-Feb;9(1 Pt 1):101-11 [9468403.001]
  • [Cites] Radiology. 2004 Aug;232(2):482-90 [15286318.001]
  • [Cites] Korean J Radiol. 2006 Apr-Jun;7(2):106-17 [16799271.001]
  • [Cites] IEEE Trans Biomed Eng. 2001 Oct;48(10):1145-52 [11585038.001]
  • [Cites] Gut. 2005 Aug;54(8):1151-6 [16009687.001]
  • [Cites] J Vasc Interv Radiol. 2005 Apr;16(4):485-91 [15802448.001]
  • [Cites] Eur Radiol. 2006 Aug;16(8):1826-34 [16541228.001]
  • [Cites] J Vasc Interv Radiol. 2000 Sep;11(8):1069-75 [10997473.001]
  • [Cites] Rofo. 2004 Mar;176(3):324-9 [15026944.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1342-4 [15684315.001]
  • [Cites] J Vasc Interv Radiol. 2003 Nov;14(11):1437-42 [14605110.001]
  • [Cites] Radiology. 2001 Oct;221(1):159-66 [11568334.001]
  • [Cites] Radiology. 2005 Dec;237(3):1056-62 [16237132.001]
  • [Cites] Radiology. 2005 Mar;234(3):954-60 [15681691.001]
  • [Cites] Radiology. 2003 Nov;229(2):447-56 [14512509.001]
  • [Cites] Cancer. 2003 Jun 15;97(12):3027-35 [12784338.001]
  • [Cites] J Am Coll Surg. 2004 May;198(5):717-21 [15110804.001]
  • [Cites] Radiology. 2006 Jan;238(1):346-53 [16373776.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):695-700 [12933462.001]
  • [Cites] Hepatology. 2005 Nov;42(5):1208-36 [16250051.001]
  • [Cites] J Digit Imaging. 2004 Sep;17(3):205-16 [15534753.001]
  • [Cites] J Vasc Interv Radiol. 2001 Jan;12(1):55-9 [11200354.001]
  • [Cites] Eur Radiol. 2003 May;13(5):1100-5 [12695834.001]
  • [Cites] J Clin Oncol. 2005 Mar 1;23(7):1358-64 [15684312.001]
  • (PMID = 17375306.001).
  • [ISSN] 0938-7994
  • [Journal-full-title] European radiology
  • [ISO-abbreviation] Eur Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Contrast Media
  •  go-up   go-down


96. Homayounfar K, Gunawan B, Cameron S, Haller F, Baumhoer D, Uecker S, Sander B, Ramadori G, Lorf T, Füzesi L: Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization. Hum Pathol; 2009 Jun;40(6):834-42
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pattern of chromosomal aberrations in primary liver cancers identified by comparative genomic hybridization.
  • Little is known about the molecular cytogenetic changes in cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma, and on the prognostic significance of chromosomal imbalances in hepatocellular carcinoma.
  • Seventy-eight cases of primary liver cancer with available median follow-up of 16.5 months, including 49 hepatocellular carcinomas, 22 cholangiocarcinomas, and 7 combined hepatocellular-cholangiocarcinomas, were examined by comparative genomic hybridization.
  • In hepatocellular carcinoma, the most frequent changes were +8q (54%), -8p (54%), and +1q (42%), followed by -6q (35%), -4q (33%), -13q (29%), -14q (25%), -16q (19%), -17p (19%), +17q (17%), and +20q (15%).
  • In comparison, cholangiocarcinoma had more gains, losses, and breakpoints than hepatocellular carcinoma or combined hepatocellular-cholangiocarcinoma, specifically more frequently -6q (91%), -3p (68%), -9p (55%), -14q (55%), -13q (45%), +1q (41%), +7q (36%), +7p (32%), and +8q (32%).
  • In contrast, combined hepatocellular-cholangiocarcinoma shared frequent +1q (71%), +8q (57%), and -8p (57%) with hepatocellular carcinoma, but a tendency for higher numbers of imbalances with cholangiocarcinoma.
  • Overall, higher numbers of changes, breakpoints, or gains appeared to carry unfavorable prognostic value among hepatocellular carcinomas, with higher numbers of gains retaining prognostic value among R0-resected hepatocellular carcinomas.
  • On the other hand, combined hepatocellular-cholangiocarcinoma may share similar chromosomal changes with both hepatocellular carcinoma and cholangiocarcinoma, as reflected by common hepatocellular carcinoma-like +8q, +1q, and -8p and a tendency for cholangiocarcinoma-like chromosomal instability.
  • In hepatocellular carcinoma, higher number of gains may prove an adverse prognostic parameter.
  • [MeSH-major] Chromosome Aberrations. Liver Neoplasms / genetics
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Hepatocellular / genetics. Carcinoma, Hepatocellular / pathology. Cholangiocarcinoma / genetics. Cholangiocarcinoma / pathology. Comparative Genomic Hybridization. Female. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19200581.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


97. Santambrogio R, Opocher E, Costa M, Bruno S, Ceretti AP, Spina GP: Natural history of a randomized trial comparing distal spleno-renal shunt with endoscopic sclerotherapy in the prevention of variceal rebleeding: a lesson from the past. World J Gastroenterol; 2006 Oct 21;12(39):6331-8
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • METHODS: In 1984 we started a prospective, controlled study of patients with liver cirrhosis.
  • Long-term follow-up presents a natural history of liver cirrhosis complicated by advanced portal hypertension.
  • The primary cause of death became hepatocellular carcinoma (HCC).
  • CONCLUSION: In a subgroup of patients with good liver function, DSRS with a correct portal-azygos disconnection more effectively prevents variceal rebleeding than ES.
  • [MeSH-major] Endoscopy, Gastrointestinal / methods. Esophageal and Gastric Varices / prevention & control. Gastrointestinal Hemorrhage / prevention & control. Liver Cirrhosis / complications. Sclerotherapy / methods. Splenorenal Shunt, Surgical / methods
  • [MeSH-minor] Adult. Female. Follow-Up Studies. Humans. Hypertension, Portal / complications. Hypertension, Portal / physiopathology. Longitudinal Studies. Male. Middle Aged. Randomized Controlled Trials as Topic. Secondary Prevention. Survival Rate

  • MedlinePlus Health Information. consumer health - Cirrhosis.
  • MedlinePlus Health Information. consumer health - Gastrointestinal Bleeding.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg. 1980 Jan;139(1):132-41 [7350837.001]
  • [Cites] Ann Surg. 1977 Feb;185(2):224-8 [300005.001]
  • [Cites] Gastroenterology. 1981 Apr;80(4):800-9 [6970703.001]
  • [Cites] Ann Surg. 1982 May;195(5):530-42 [7073351.001]
  • [Cites] Hepatology. 1983 Sep-Oct;3(5):681-4 [6352448.001]
  • [Cites] Lancet. 1983 Dec 10;2(8363):1328-32 [6139669.001]
  • [Cites] N Engl J Med. 1984 Dec 20;311(25):1594-600 [6390203.001]
  • [Cites] World J Surg. 1984 Oct;8(5):722-32 [6390991.001]
  • [Cites] Hepatology. 1985 Jul-Aug;5(4):584-9 [3894200.001]
  • [Cites] Hepatology. 1985 Sep-Oct;5(5):827-30 [2993147.001]
  • [Cites] Gut. 1986 Jun;27(6):710-3 [3522372.001]
  • [Cites] Br J Surg. 1986 Sep;73(9):708-11 [3756433.001]
  • [Cites] Ann Surg. 1986 Oct;204(4):346-55 [3532968.001]
  • [Cites] Hepatology. 1987 Mar-Apr;7(2):355-61 [3549507.001]
  • [Cites] Hepatology. 1987 May-Jun;7(3):430-6 [3552920.001]
  • [Cites] Hepatology. 1987 May-Jun;7(3):437-41 [3552921.001]
  • [Cites] Surg Gynecol Obstet. 1987 Jun;164(6):530-6 [3495894.001]
  • [Cites] Int Surg. 1987 Jul-Sep;72(3):144-8 [3679731.001]
  • [Cites] Am J Surg. 1988 Apr;155(4):564-71 [3354781.001]
  • [Cites] Ann Surg. 1988 Jul;208(1):104-9 [3389941.001]
  • [Cites] Ann Intern Med. 1990 Feb 15;112(4):262-9 [2404448.001]
  • [Cites] Ann Surg. 1990 Feb;211(2):178-86 [2405792.001]
  • [Cites] Am J Surg. 1993 Jan;165(1):27-32; discussion 32-3 [8418700.001]
  • [Cites] J Hepatol. 1992 Nov;16(3):338-45 [1487611.001]
  • [Cites] Radiology. 1999 Aug;212(2):411-21 [10429698.001]
  • [Cites] Hepatology. 1999 Sep;30(3):612-22 [10462365.001]
  • [Cites] Dig Liver Dis. 2004 Dec;36(12):787-98 [15646423.001]
  • [Cites] Ann Surg. 2005 Feb;241(2):238-46 [15650633.001]
  • [Cites] J Chin Med Assoc. 2004 Nov;67(11):557-64 [15720069.001]
  • [Cites] Hepatology. 2005 Mar;41(3):566-71 [15726654.001]
  • [Cites] Gastroenterology. 1977 Apr;72(4 Pt 1):573-83 [14049.001]
  • [Cites] Semin Liver Dis. 1999;19(4):439-55 [10643628.001]
  • [Cites] Surgery. 2000 Jun;127(6):614-21 [10840355.001]
  • [Cites] Arch Surg. 2001 Jan;136(1):17-20 [11146768.001]
  • [Cites] Hepatogastroenterology. 2001 Jul-Aug;48(40):1110-3 [11490812.001]
  • [Cites] Stat Med. 2003 Feb 28;22(4):559-71 [12590414.001]
  • [Cites] J Hepatol. 2003;38 Suppl 1:S54-68 [12591186.001]
  • [Cites] Ann Surg. 1967 Sep;166(3):437-55 [6068492.001]
  • [Cites] Br J Surg. 1973 Aug;60(8):646-9 [4541913.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Jpn J Surg. 1980 Mar;10(1):84-7 [7373958.001]
  • (PMID = 17072957.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Randomized Controlled Trial
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC4088142
  •  go-up   go-down


98. Sun JH, Wang LG, Bao HW, Lou JL, Cai LX, Wu C, Chen LM, Zheng SS: Usefulness of C-arm angiographic computed tomography for detecting iodized oil retention during transcatheter arterial chemoembolization of hepatocellular carcinoma. J Int Med Res; 2010 Jul-Aug;38(4):1259-65
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Usefulness of C-arm angiographic computed tomography for detecting iodized oil retention during transcatheter arterial chemoembolization of hepatocellular carcinoma.
  • Transcatheter arterial chemoembolization (TACE) with iodized oil and anticancer agents is widely used for hepatocellular carcinoma (HCC) treatment.
  • The primary CCT images showed complete iodized oil retention patterns (type I) in 29/40 (73%) tumours, at which point embolization was terminated; incomplete iodized oil retention requiring further iodized oil embolization occurred in 11/40 (28%) tumours and, of these, complete iodized oil retention patterns were achieved in eight tumours.
  • [MeSH-major] Angiography / instrumentation. Carcinoma, Hepatocellular / drug therapy. Catheterization / methods. Chemoembolization, Therapeutic / methods. Iodized Oil / therapeutic use. Liver Neoplasms / drug therapy. Tomography, X-Ray Computed / instrumentation
  • [MeSH-minor] Adult. Aged. Female. Fluoroscopy. Humans. Male. Middle Aged

  • MedlinePlus Health Information. consumer health - CT Scans.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20925998.001).
  • [ISSN] 0300-0605
  • [Journal-full-title] The Journal of international medical research
  • [ISO-abbreviation] J. Int. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 8001-40-9 / Iodized Oil
  •  go-up   go-down


99. Gruttadauria S, Marsh JW, Cintorino D, Biondo D, Luca A, Arcadipane A, Vizzini G, Volpes R, Marcos A, Gridelli B: Adult to adult living-related liver transplant: report on an initial experience in Italy. Dig Liver Dis; 2007 Apr;39(4):342-50
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adult to adult living-related liver transplant: report on an initial experience in Italy.
  • INTRODUCTION: Living-related liver transplantation has become the treatment of choice for many liver diseases.
  • We present our initial analysis of 53 cases of adult to adult living-related liver transplantation performed in a single institute in Italy.
  • MATERIALS AND METHODS: From January 2002 to September 2006, we performed 53 adult to adult living-related liver transplantations.
  • Recipients (ages 18-68) suffered from cirrhosis secondary to viral etiology (18), hepatocellular carcinoma with viral cirrhosis (24), cystic fibrosis (2), primary biliary cirrhosis (2), hepatocellular carcinoma with non-viral cirrhosis (2), alcoholic cirrhosis (1), ornithine transcarbamylase deficiency (OTC), (1) criptogenic cryptogenic cirrhosis, (1) primary sclerosing cholangitis, (1) biliary atresia and metastatic carcinoid (1).
  • Donor liver resection resulted in 51 right hepatectomies and two left hepatectomies.
  • CONCLUSION: Adult to adult living-related liver transplantation represents a resource to be used in confronting organ shortage, and is a valuable option for decreasing mortality and drop out from the waiting list.
  • [MeSH-major] Liver Transplantation / statistics & numerical data. Living Donors
  • [MeSH-minor] Adolescent. Adult. Donor Selection. Female. Graft Rejection / epidemiology. Graft Survival. Humans. Italy / epidemiology. Liver Diseases / mortality. Liver Diseases / surgery. Male. Middle Aged. Recurrence. Reoperation / statistics & numerical data. Treatment Outcome

  • Genetic Alliance. consumer health - Liver Transplant.
  • MedlinePlus Health Information. consumer health - Liver Transplantation.
  • MedlinePlus Health Information. consumer health - Organ Donation.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17337259.001).
  • [ISSN] 1590-8658
  • [Journal-full-title] Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
  • [ISO-abbreviation] Dig Liver Dis
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


100. Henderson WA, Shankar R, Gill JM, Kim KH, Ghany MG, Skanderson M, Butt AA: Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma. J Viral Hepat; 2010 Jan;17(1):59-64
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Hepatitis C progressing to hepatocellular carcinoma: the HCV dialysis patient in dilemma.
  • Approximately 3.2 million people in the United States have chronic hepatitis C virus (HCV) infection; the primary cause for adult liver transplantation and a significant burden on healthcare resources.
  • We studied predictors of hepatocellular carcinoma (HCC) in dialysis patients with chronic HCV by analyzing factors associated with its development.

  • Genetic Alliance. consumer health - Hepatitis.
  • Genetic Alliance. consumer health - Hepatitis C (HCV).
  • MedlinePlus Health Information. consumer health - Dialysis.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Artif Organs. 2001 Jan;25(1):58-60 [11167561.001]
  • [Cites] J Clin Gastroenterol. 2008 Oct;42(9):1054-59 [19013829.001]
  • [Cites] Hepatology. 2002 Nov;36(5 Suppl 1):S74-83 [12407579.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):702-10 [12594314.001]
  • [Cites] Rev Gastroenterol Disord. 2003 Summer;3(3):125-34 [14502116.001]
  • [Cites] Ann Intern Med. 2003 Nov 18;139(10):817-23 [14623619.001]
  • [Cites] Hepatology. 2004 Jul;40(1):115-9 [15239093.001]
  • [Cites] Clin Gastroenterol Hepatol. 2004 Sep;2(9):820-4 [15354283.001]
  • [Cites] Hepatology. 1990 Oct;12(4 Pt 1):671-5 [2170265.001]
  • [Cites] Am J Kidney Dis. 1993 Oct;22(4):568-73 [8213797.001]
  • [Cites] ASAIO J. 1997 Jan-Feb;43(1):108-19 [9116344.001]
  • [Cites] Am J Kidney Dis. 1998 Oct;32(4):629-34 [9774125.001]
  • [Cites] Nephron. 1998 Dec;80(4):428-33 [9832642.001]
  • [Cites] Arch Intern Med. 2004 Nov 22;164(21):2349-54 [15557414.001]
  • [Cites] Am J Gastroenterol. 2005 Jan;100(1):56-63 [15654781.001]
  • [Cites] J Hepatol. 2005 Mar;42(3):309-14 [15710213.001]
  • [Cites] J Hepatol. 2006 May;44(5):864-8 [16516332.001]
  • [Cites] Ann Intern Med. 2006 May 16;144(10):705-14 [16702586.001]
  • [Cites] Am J Gastroenterol. 2006 Dec;101(12):2737-43 [17227521.001]
  • [Cites] JAMA. 2007 May 9;297(18):2010-7 [17488966.001]
  • [Cites] J Viral Hepat. 2007 Oct;14(10):688-96 [17875003.001]
  • [Cites] J Viral Hepat. 2007 Oct;14(10):697-703 [17875004.001]
  • [Cites] J Natl Cancer Inst. 2008 Aug 20;100(16):1134-43 [18695135.001]
  • [Cites] Nephrol Dial Transplant. 2001 Aug;16(8):1669-74 [11477172.001]
  • (PMID = 19566787.001).
  • [ISSN] 1365-2893
  • [Journal-full-title] Journal of viral hepatitis
  • [ISO-abbreviation] J. Viral Hepat.
  • [Language] ENG
  • [Grant] United States / NCATS NIH HHS / TR / TL1 TR000145; United States / NCRR NIH HHS / RR / TL1 RR024155; United States / NINR NIH HHS / NR / P30 NR003924-07; United States / Intramural NIH HHS / / ZIA NR000018-01; United States / Intramural NIH HHS / / Z99 NR999999; United States / NIDA NIH HHS / DA / DA016175-01A1; United States / NIDA NIH HHS / DA / K23 DA016175; United States / NIDA NIH HHS / DA / K23 DA016175-01A1; United States / NCRR NIH HHS / RR / RR024155-01; United States / NCRR NIH HHS / RR / TL1 RR024155-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ NIHMS183154; NLM/ PMC2956610
  •  go-up   go-down






Advertisement